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Th e prostate is an exocrine gland of the male reproductive system. It is about the size of 
a chestnut and it is located caudally of the bladder, encompassing the proximal urethra. It 
produces secretions that form the major components of the ejaculate.
Adenocarcinoma of the prostate or prostate cancer (PCa) is the most common malignancy 
in Dutch men. A Dutch man has a lifetime chance of 9.8% of being diagnosed with PCa 
[1]. In the year 2006, 9,516 Dutch men were diagnosed with PCa and 2,394 died from this 
disease (http://www.ikcnet.nl, accessed on February 19th 2009).
Normally, PCa is diagnosed by the histological examination of prostate tissue that is 
obtained by ultrasound guided transrectal biopsy. Indications for biopsy are predominantly 
an increased serum level of prostate-specifi c antigen (PSA) and/or an aberrant digital rectal 
examination (DRE). PSA is the standard diagnostic and prognostic PCa marker. PCa 
awareness, leading to widespread use of PSA testing has led to a lower tumor stage and grade 
at the time of diagnosis. However, the use of PSA is associated with certain drawbacks.
Th e limitations of PSA will be discussed in chapter 2. Fortunately, there are many markers 
showing promise to overcome these limitations. Eventually, these markers should be able to 
increase the specifi city in diagnosis, diff erentiate between harmless and aggressive disease 
and identify progression towards androgen independence at an early stage. In chapter 2, 
an overview is given of serum and urine PCa markers that are currently under investigation 
and subsequently the P-Mark project is introduced. In the P-Mark project, several recently 
developed, promising markers will be evaluated using clinically well-defi ned biorepositories. 
Following successful evaluation, these markers will be validated on a sample set derived from 
two large, European, PCa studies and used for the identifi cation of special risk groups in the 
general population. In addition, novel markers will be identifi ed in the same biorepositories 
by diff erent mass spectrometry techniques.
To improve the specifi city in PCa diagnosis and to prevent unnecessary prostate biopsies, 
especially in the serum PSA ‘gray zone’ between 3 and 15 ng/ml, the implementation of 
PCa-specifi c markers is urgently needed. In a previous single institution study in 2003, the 
PCA3 urine test clearly proved to be of diagnostic value [2]. In chapter 3, the diagnostic 
performance of the PCA3 urine test was validated in a Dutch multicenter study by correlating 
the PCA3 score in urinary sediments aft er DRE with the presence of PCa in subsequent 
prostate biopsies.
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Th e rationale for the molecular PCA3 test on urine is as follows. Both prostate and 
PCa cells shed into the prostatic ductal system. Upon DRE cells are mobilized towards the 
prostatic urethra and upon micturition they are fl ushed out with the fi rst voided urine. From 
clinical practice it is known that occasionally during DRE a patient will produce a few drops 
of prostatic fl uid from the meatus. Naturally, this fl uid should also contain prostate and 
PCa cells. Consequently, prostatic fl uid may be a suitable substrate for the PCA3 test. Upon 
micturition the cells remaining in the (prostatic) urethra will be fl ushed out with the fi rst 
voided urine. In chapter 4, we compared the diagnostic value of the PCA3 test on prostatic 
fl uid with that on urine aft er DRE in men who were to undergo prostate biopsies.
PCA3 gene-based testing on urine samples has shown promise to improve the specifi city 
in PCa diagnosis and to reduce the number of unnecessary prostate biopsies, and to predict 
repeat biopsy outcomes. However, so far few attempts have been made to investigate the 
prognostic value of PCA3. We hypothesized that since aggressive PCa cells are more 
invasive, they would be more likely to mobilize and shed into the prostate ductal system. 
Th is would result in a higher percentage of PCa cells to be collected with the fi rst voided 
urine aft er DRE and thus a higher PCA3 score. Chapter 5 describes a study in which the 
PCA3 score in urinary sediments aft er DRE was correlated to the biopsy Gleason score (GS) 
and clinical stage in men admitted for prostate biopsies based on serum PSA levels > 3 ng/
ml, an abnormal DRE, and/or a family history of PCa. Moreover, in men who underwent a 
radical prostatectomy, the correlation of PCA3 with prostatectomy GS, tumor volume and 
pathological stage was assessed as well.
In addition to chapter 5 and to further investigate the prognostic value of PCA3, 
chapter 6 describes a study in which we analyzed the correlation between the PCA3 score 
in urinary sediments aft er DRE and the classical prognostic parameters assessed in radical 
prostatectomy specimens, i.e. GS, tumor stage and total tumor volume. Moreover, we analyzed 
the correlation between the PCA3 score and the expression of three immunohistochemical 
markers for PCa biological aggressiveness: the cell-cell adhesion molecules E-cadherin and 
α-catenin, and the human homolog of the Drosophila enhancer of zeste gene (EZH2).
Dutasteride is commonly used in patients that are also at risk for PCa. Th erefore, 
the infl uence of dutasteride on PCa markers has to be studied. To date only the eff ect of 
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dutasteride on serum PSA has been studied. In chapter 7, the results are presented of the fi rst 
study to investigate the eff ect of dutasteride on the PCA3 score, longitudinally and in a dose 
dependent manner in both men with benign prostatic hyperplasia and men with PCa.
In chapter 8 the overview of serum and urine PCa markers from chapter 2 is updated. 
Th is is followed by the general discussion and future perspectives to complete the thesis. 
A summary is provided in chapter 9.
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Abstract
An overview is given of serum and urine prostate cancer markers that are currently under 
investigation and subsequently the P-Mark project is introduced.
Th ere are many markers showing promise to overcome the limitations of prostate-
specifi c antigen (PSA). Eventually, these markers should be able to increase the specifi city 
in diagnosis, diff erentiate between harmless and aggressive disease and identify progression 
towards androgen independence at an early stage.
In the P-Mark project, several recently developed, promising markers will be evaluated 
using clinically well-defi ned biorepositories. Following successful evaluation, these markers 
will be validated on a sample set derived from two large, European, prostate cancer studies 
and used for the identifi cation of special risk groups in the general population. In addition, 
novel markers will be identifi ed in the same biorepositories by diff erent mass spectrometry 
techniques.
Introduction
Prostate cancer (PCa) is the most common malignancy in European males. In 2002 in 
Europe, an estimated 225,000 men were newly diagnosed with PCa and about 83,000 died 
from this disease (http://www-dep.iarc.fr) [1]. PCa is diagnosed by histological examination 
of prostate tissue that is obtained by ultrasound guided transrectal biopsy. Indications for 
biopsy are predominantly an increased serum prostate-specifi c antigen (PSA) and/or an 
aberrant digital rectal examination.
PSA is the standard diagnostic and prognostic PCa marker. PCa awareness, leading 
to widespread use of PSA testing has led to a lower tumor stage and grade at the time of 
diagnosis. However, the use of PSA is associated with certain drawbacks.
Firstly, PSA is not cancer-specifi c. An increase in PSA can refl ect benign rather than 
malignant prostatic disease. Conditions as benign prostatic hyperplasia or prostatitis can 
lead to an elevated PSA value, resulting in a negative biopsy rate of 70-80%. A large number 
of prostate biopsies is therefore unnecessary.
Secondly, increased detection has led to the diagnosis of clinically irrelevant tumors, i.e. 
overdiagnosis, and overtreatment. Overdiagnosis is defi ned as the diagnosis of a disease entity, 
which in the absence of screening would not be diagnosed during the lifetime of its carrier. 
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If overdiagnosis leads to the (unnecessary) treatment of the disease, the term overtreatment 
is applied [2].
Th irdly, there is the problem of men with clinically localized disease, but who have 
undetected micrometastases. Th ese will lead to symptomatic cancers in due time. At present, 
such men are incurable. However, if they could be identifi ed appropriately, they should be 
considered for adjuvant therapy at the time of primary treatment. Lastly, many PCa patients 
who are not cured by radical therapy will ultimately develop hormone independence and 
treatment resistance. Early recognition of androgen independence may be an indication for 
systemic treatment by one of many second line treatments at a phase of low tumor burden. 
However, currently it is impossible to predict therapy resistance at an early stage.
As a result from these drawbacks, new PCa markers are needed. Th ese new markers should 
increase specifi city in PCa diagnosis, be able to diff erentiate between harmless and aggressive 
disease and be able to predict PCa androgen independency at an early stage. Serum and urine 
contain degradation products of extracellular matrix and of benign and malignant cells and 
their secreted products. Th ese will appear in plasma and urine. Determination of markers 
in these fl uids has certain advantages over the use of tissue markers (Figure 1). Even though 
the release of PCa-related proteins and/or peptides into plasma and urine incompletely 
refl ects tumor metabolism, these body fl uids can easily be obtained. In contrast, prostate 
tissue sampling requires an invasive procedure (i.e. transrectal ultrasound-guided biopsy). 
Furthermore, sampling error is an important problem. For example, the tumor can be missed 
completely causing a false-negative test result. On the other hand, a positive biopsy may not 
be representative of the tumor, due to the oft en polyclonal nature of PCa.
In the fi rst part of this article an overview is given of serum and urine PCa markers that 
are currently under investigation. In the second part, the P-Mark project is introduced.
PCa markers
PCa markers can be classifi ed into four diff erent categories: prostate-specifi c proteins, genetic 
variations in PCa, genes overexpressed in PCa, and markers of bone metabolism. Markers in 
these four categories will now be discussed and an overview is provided in Table I.
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Figure 1. Serum and urine prostate cancer markers have certain advantages over tissue prostate cancer 
markers. Serum and urine can easily be obtained. In contrast, prostate tissue sampling requires an invasive 
procedure (transrectal ultrasound-guided biopsy) and sampling error is an important problem.
Table I. Serum and urine prostate cancer markers
Marker Type Method Sample type Purpose
Prostate-specifi c 
proteins
Prostate-specifi c antigen Protein Commercially available 
immunoassays
Serum Standard marker
Various forms of 
prostate-specifi c antigen
Protein Research use and 
commercially available 
immunoassays
Serum Early diagnosis
Human kallikrein 2 Protein Research use and 
commercially available 
immunoassays
Serum Early diagnosis
Markers of neuro-
endocrine diff erentiation
Protein Commercially available 
immunoassays
Serum Prognosis
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Marker (Continued) Type Method Sample type Purpose
Genetic variations in prostate cancer
Polymorphisms in 
cytochrome P450 
enzyme superfamily 
genes
Genetic 
polymorphism
PCR-RFLP* Serum Risk stratifi cation
π-class glutathione 
S-transferase 1 
gene promoter 
hypermethylation
Epigenetic DNA 
alteration
MSP* Urine Early diagnosis
TMPRSS2-ETS gene 
fusions
Gene fusions RT-PCR* Urine Early diagnosis
Genes overexpressed in prostate cancer
PCA3 Non-coding mRNA RT-PCR* Urine Early diagnosis and 
prognosis
Prostate-specifi c 
membrane antigen
Protein Research use immunoassay** Serum Early diagnosis
Telomerase Protein Commercially available 
immunoassay
Urine Early diagnosis
Early prostate cancer 
antigen
Protein Research use immunoassay Serum Early diagnosis
CRISP-3 Protein Research use immunoassay Serum Early diagnosis
Alpha-methylacyl-
coenzym-A racemase
Protein Commercially available and 
research use immunoassay
Serum and 
urine
Early diagnosis
Hepsin Protein Commercially available 
immunoassay
Non applicable Early diagnosis
Markers of bone metabolism
Markers of bone 
formation
Peptide or protein Commercially available 
immunoassays
Serum Prognosis
Markers of bone 
resorption
Amino acid or 
peptide
Commercially available 
immunoassays
Serum and 
urine
Prognosis
Bone morphogenetic 
protein 6
Protein Research use immunoassay Serum Prognosis
Osteoprotegerin Protein Commercially available 
immunoassay
Serum Prognosis
* PCR-RFLP (polymerase chain reaction restriction fragment length polymorphism), MSP (methylation-specifi c polymerase chain 
reaction) and RT-PCR (reverse transcriptase polymerase chain reaction) are assays described in the text.
** In combination with SELDI-TOF MS (surface-enhanced laser desorption ionization time-of-fl ight mass spectrometry), a mass 
spectrometry technique described in the text.
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1. Prostate-specifi c proteins
1.1 PSA
Th e prostate gland produces a number of proteins (e.g. PSA) that are secreted into seminal 
fl uid. PSA is a serine protease belonging to the human kallikrein (hK) family and is also 
known as hK3. PSA is formed in the prostatic epithelium and secreted into the prostatic 
ducts. Its function is to digest the gel that is formed in semen aft er ejaculation. Normally, 
only a minor fraction of PSA leaks into the extracellular space and into circulation. When 
tissue architecture is distorted in PCa, serum PSA will increase. PSA is produced as a 
preproenzyme comprising 261 amino acids, including a signal peptide that is 17 amino acids 
long and is removed during synthesis. Th e secreted proenzyme (proPSA) thus contains 244 
amino acids including a 7 amino acid activation peptide, which is split off  aft er secretion. 
Mature (free) PSA thus contains 237 amino acids. PSA isolated from seminal fl uid is 
partially degraded by proteolytic cleavage (i.e. nicking) at certain sites, producing nicked 
free PSA. PSA detected by immunoassays is mainly complexed with protease inhibitors, 
predominantly with α1-antichymotrypsin (ACT), while minor parts occur in complex with 
α2-macroglobulin (AMG) and α1-protease inhibitor (API). A certain percentage of PSA (i.e. 
5-35%) will remain unbound.
In spite of its limitations, PSA is the standard diagnostic and prognostic PCa marker. 
Modifi cations in standard PSA testing overcome some of these limitations. Th e ratio of total 
PSA to total prostate volume or to prostate transition zone volume (i.e. PSA density or PSA 
transition zone density respectively) can increase diagnostic specifi city [3]. However, the 
need for prostate volume measurement by transrectal ultrasound, which is hampered by 
interobserver variability, makes this of little use for screening purposes.
Another modifi cation in standard PSA testing is PSA doubling time. Th is, rather 
than PSA velocity (i.e. the rate of increase in serum PSA), is a useful tool aft er primary 
treatment for clinically localized PCa with curative intent. As a rise in serum PSA (i.e. 
biochemical recurrence) is usually the fi rst evidence of either local recurrence or metastatic 
progression [4].
1.2 Various forms of PSA
Th e free fraction of PSA occurs in several diff erent forms, e.g. proPSA, active PSA and nicked 
PSA. Specifi c determinations of these forms may improve PCa diagnosis, presumably because 
PSA processing is diff erent in PCa and benign tissue.
Innovations in serum and urine markers in prostate cancer
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Th e percentage free PSA is decreased in PCa as compared to benign prostatic hyperplasia 
[5]. Using either logistic regression or artifi cial neural networks to estimate the combined 
impact of total and free PSA and the results of clinical examinations, can lead to further 
improvement of diagnostic specifi city for PCa [6]. Additionally, the percentage of free PSA 
correlates with PCa stage and grade [7].
As the percentage free PSA is lower in PCa patients, the percentage of PSA complexed 
with protease inhibitors should be increased. Th is has been confi rmed for the complex of 
PSA and ACT (PSA-ACT) [8]. On the other hand, the percentage PSA-AMG is decreased 
in PCa [9] and so is the percentage PSA-API. A commercially available assay for ‘complexed 
PSA’ has the theoretical weakness of measuring the sum of both serum PSA-ACT and PSA-
API. However, because the contribution of PSA-API is small, this assay still shows elevated 
levels in PCa patients [10].
Th e percentage proPSA (i.e. the proenzyme form of PSA) is elevated in PCa patients 
[11]. Th e percentage nicked free PSA is decreased in PCa patients (i.e. a larger percentage is 
therefore intact) [12].
1.3 Human kallikrein 2
Human kallikrein 2 (hK2) is a prostate-specifi c serine protease that is 80% homologous to 
PSA. However, while PSA displays chymotrypsin-like specifi city, hK2 is trypsin-like. Th us, 
hK2 can cleave proPSA to form mature (free) PSA. Serum concentrations of hK2 are 50- 
to 100-fold lower than those of PSA. While the expression of PSA tends to decrease with 
increasing PCa tumor grade, that of hK2 increases or remains constant. Th erefore, hK2 may 
not only improve PCa diagnosis, but also act as a marker of advanced grade [13]. However, 
this has not been confi rmed by other studies [14].
1.4 Markers of neuro-endocrine diff erentiation
Th e prostatic epithelium contains neuro-endocrine cells that are thought to be androgen-
independent. Th e function of these cells is largely unknown. Th ey might induce proliferation 
of adjacent cells by paracrine stimulation. Some reports suggest that the number of neuro-
endocrine cells is associated with PCa prognosis [15], but there is considerable discrepancy 
in the literature.
Neuro-endocrine cells form chromogranin A (CgA), a precursor for several biologically 
active peptides (e.g. vasostatin I and II). Although not helpful in early diagnosis, as a marker of 
neuro-endocrine diff erentiation, CgA could possibly refl ect androgen-independent disease. 
Increased serum levels appear to correlate with adverse prognosis in patients with hormone 
therapy resistant, metastatic PCa [16].
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Irrespective of the serum CgA level, a high serum level of neuron-specifi c enolase (NSE), 
another neuro-endocrine marker, also predicts adverse prognosis in metastatic PCa patients 
treated with endocrine therapy [17].
2. Genetic variations in PCa
Certain genetic polymorphisms and epigenetic DNA alterations are associated with PCa. 
A genetic polymorphism is the simultaneous existence of diff erent genotypes of a gene in a 
population (e.g. the ABO blood-group system). Th e diff erent forms of a gene are called alleles 
(e.g. the ‘A’, ‘B’ and ‘O’ alleles) and, as humans are diploid organisms, the genotype is formed 
by the two alleles of every gene. Genetic polymorphisms can be detected by polymerase 
chain reaction restriction fragment length polymorphism (PCR-RFLP). Th e polymerase 
chain reaction (PCR) is a method to produce a large number of copies of specifi c DNA 
target fragments using short, complementary, neighbouring, oligonucleotide sequences 
(i.e. primers) and a DNA duplicating enzyme (i.e. DNA polymerase). Restriction fragment 
length polymorphism includes DNA digestion by restriction enzymes. Diff erent genetic 
polymorphisms will have diff erent recognition sites for restriction enzymes and therefore 
generate DNA fragments of diff erent lengths.
Epigenetic DNA alterations are modifi cations in DNA that do not change the base-
sequence. Promoter hypermethylation of a gene is an epigenetic alteration. Methylation-
specifi c polymerase chain reaction (MSP) is a variation of the PCR technique, capable of 
identifying hypermethylated alleles in DNA.
2.1 Genetic polymorphisms in cytochrome P450 enzyme superfamily
Th e cytochrome P450 enzyme superfamily (CYP) is involved in the metabolism of many 
endogenous and exogenous substances, including androgens. Th e role of these enzymes in 
PCa has been the focus of investigation, as blood androgen levels could be associated with 
the risk of developing this disease.
Th e CYP3A gene is involved in the oxidation of testosterone. Th erefore, genetic 
polymorphisms in this subfamily have been linked with PCa. In the past, the CYP3A4*1B 
polymorphism was shown to correlate with higher PCa grade and stage [18]. However, this 
could be the result of linkage with the CYP3A5*3 polymorphism that was associated with 
more aggressive tumors as well [19]. Compared to the CYP3A4*1B polymorphism however, 
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the CYP3A5*3 polymorphism is much more common in Caucasians [18-20], e.g. only one 
in 500 healthy Dutch Caucasians was homozygote for the wildtype allele (i.e. did not have 
any CYP3A5*3 alleles) [21].
In addition, genetic polymorphisms in both the CYP1A1 and the CYP1B1 gene may 
modify the risk for PCa, possibly on account of their functions in activating environmental 
procarcinogens and the metabolism of estrogens [22,23].
2.2 π-class glutathione S-transferase 1 gene promoter hypermethylation
π-class glutathione S-transferase 1 (GSTP1) functions as a detoxifi cation enzyme. Promoter 
hypermethylation of its gene leads to decreased expression. Th is has been identifi ed as the 
most common epigenetic DNA alteration associated with PCa.
Using MSP, GSTP1 gene promoter hypermethylation was studied in prostate cells that 
were shed in urinary sediments by thorough digital rectal examination. Th is test proved 
highly PCa-specifi c, showing potential to improve PCa diagnosis and reduce the number of 
unnecessary biopsies [24].
2.3 TMPRSS2-ETS gene fusions
TMPRSS2 is a transmembrane serine protease, the expression of which is androgen-regulated 
and is higher in both malignant and benign prostate tissue compared to other human tissues 
[25].
Th e erythroblastosis virus E26 transforming sequence (ETS) family of genes encodes 
transcription factors that are central in integrating signals that regulate cell growth and 
diff erentiation, stress responses, and tumorigenesis. Petrovics et al. identifi ed ETS-related 
gene (ERG), a member of this transcription factor family, as the most frequently overexpressed 
proto-oncogene in PCa [26].
Using a novel bioinformatics approach, i.e. cancer outlier profi le analysis, Tomlins et 
al. identifi ed outlier overexpression of ERG and ETS variant 1 (ETV1), both members of 
the ETS family, in PCa. Moreover, they reported that the gene fusion of the androgen-
responsive promoter elements of the TMPRSS2 gene to either ERG or ETV1 caused this 
overexpression [27]. As TMPRSS2-ETS gene fusions are PCa-specifi c, they could be very 
useful as diagnostic PCa markers.
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3. Genes overexpressed in PCa
Changes in gene expression are believed to form the basis of many physiologic and 
pathophysiologic processes (e.g. cancer). Genes overexpressed in PCa can be discovered by 
comparing the gene expression in PCa tissue with the gene expression in non-malignant 
prostate tissue, e.g. by diff erential display analysis. Using this method, all the mRNA in cells 
is quantifi ed by the reverse transcriptase polymerase chain reaction (RT-PCR) and aft er 
quantifi cation, diff erences in genetic expression can be analyzed. PCR was described earlier. 
RT-PCR is a variation of the PCR technique in which complementary DNA is fi rst made 
from RNA via reverse transcription. PCA3 was identifi ed using diff erential display analysis 
[28].
3.1 PCA3
PCA3 (formerly known as DD3 or PCA3DD3) is the most PCa-specifi c gene described to 
date. It was found to be strongly overexpressed in more than 95% of primary PCa specimens 
and in PCa metastases [28]. Furthermore, PCA3 is prostate specifi c, i.e. its expression is 
restricted to prostatic tissue only [28,29]. Th e median up-regulation of PCA3 in PCa tissue 
compared to normal prostate tissue was 66-fold. Moreover, a median upregulation of 11-fold 
was found in prostate tissues containing less than 10% of PCa cells.
As PCA3 is a non-coding mRNA, a specialized RT-PCR assay was needed to identify it 
as a diagnostic PCa marker in prostate cells in urinary sediments aft er thorough digital rectal 
examination. Th is test showed a negative predictive value of 90% in a population of men, 
admitted for prostate biopsies based on a serum PSA value > 3ng/ml. Th erefore, PCA3 has 
great potential in reducing the number of unnecessary biopsies [30].
3.2 Prostate-specifi c membrane antigen
Prostate-specifi c membrane antigen (PSMA) is a transmembrane protein, expressed pre-
dominantly in prostate tissue and was initially identifi ed in a human PCa cell line (LNCaP). 
PSMA is down-regulated in benign prostatic hyperplasia and overexpressed in primary and 
metastatic PCa.
Due to the lack of a sensitive immunoassay for the measurement of serum PSMA, the 
combination was used of an innovative immunoassay and surface-enhanced laser desorption 
ionization time-of-fl ight mass spectrometry (SELDI-TOF MS, i.e. a mass spectrometry 
technique that will be described later). Serum PSMA proved successful in diff erentiating 
benign from malignant prostate disease [31].
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3.3 Telomerase
Synthesis of DNA at chromosome ends, i.e. telomeres, by telomerase may be necessary for 
indefi nite proliferation. Kim et al. found telomerase activity in several cancers including PCa 
[32]. In a small study, telomerase activity was detected in voided urine samples or urethral 
washings aft er prostatic massage with promising sensitivity and excellent specifi city for the 
detection of PCa [33]. Comparable results were obtained in a case-control study with 60 
men using voided urine samples containing prostatic fl uid aft er prostatic massage [34], and a 
study examining post DRE urine samples from 56 men undergoing routine prostate screening 
[35]. Th us far, there have been three reports linking telomerase activity in prostatic fl uid to 
the presence of PCa [36-38]. Two small case mix studies showed promising diagnostic ability 
of telomerase activity in prostatic fl uid samples obtained by extensive prostate massage under 
general anesthesia [37,38]. A third study investigated telomerase activity in prostatic fl uid 
samples obtained by prostatic massage followed by urethral milking from 49 men undergoing 
prostate biopsy. It showed 36% sensitivity and 66% specifi city [36].
3.4 Early prostate cancer antigen
Early prostate cancer antigen (EPCA) is a nuclear matrix protein that is expressed throughout 
the prostate of individuals with PCa but not in those without the disease [39]. Paul et al. 
investigated an assay using anti-EPCA antibodies to measure the level of EPCA in the 
plasma of a case mix population of 46 subjects, including 12 PCa patients. In this small study 
the sensitivity of the EPCA assay for detecting PCa was 92% whereas the overall specifi city 
was 94% [40].
3.5 Cysteine-rich secretory protein 3
Cysteine-rich secretory protein 3 (CRISP-3), formerly known as specifi c granule protein 
of 28 kDa (SGP28), is not prostate specifi c, but it is highly overexpressed in PCa tissue 
compared to benign prostatic tissue [41]. An assay to detect CRISP-3 in body fl uids could 
thus have value in the diagnosis of PCa [42].
3.6 Alpha-methylacyl-coenzym-A racemase
Alpha-methylacyl-coenzym-A racemase (AMACR) is an enzyme involved in the catabolism 
of branched-chain fatty acids. AMACR was shown to be overexpressed in PCa tissue 
compared with benign prostate tissue resulting in a clearly increased immunohistochemical 
staining intensity [43]. Combined with a prostate basal cell marker that is absent in PCa, e.g. 
p63, AMACR is already used in clinical practice to facilitate the identifi cation of PCa cells 
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in prostate biopsies or other prostate tissue samples. Attempts to detect AMACR in blood 
have not been successful, but the detection of an endogenous humoral immune response 
against the AMACR protein showed diagnostic potential [44]. In addition, AMACR could 
be detected by Western blot in the urine of PCa patients following transrectal ultrasound 
guided prostate biopsy [45] and a small study has shown promising results of the quantitative 
detection of AMACR transcripts by RT-PCR in urine samples obtained aft er prostate 
massage [46].
3.7 Hepsin
Hepsin is a transmembrane serine protease that is overexpressed in PCa tissue compared to 
benign prostate tissue [47]. Moreover, hepsin expression was signifi cantly correlated with 
measures of clinical outcome [48]. However, hepsin overexpression has been described 
in other types of cancer and therefore a role beyond that as a PCa tissue marker seems 
inappropriate.
4. Markers of bone metabolism
PCa is recognized for its propensity to form predominantly osteoblastic and/or osteosclerotic 
bone metastases. Bone turnover markers refl ect both osteoblast activity during bone formation 
and osteoclast activity during bone resorption. Th e bony lesions have a mixed nature and 
the rate of remodelling of the bone matrix is higher in metastatic PCa patients. Th erefore, 
markers in both categories may be increased in PCa metastasis. Bone turnover markers have 
therefore been studied in PCa for many years as an indirect measurement of metastatic 
disease. Th eir usefulness is however impaired by the fact that ageing, androgen deprivation 
hormonal therapy and other, benign bone pathologies can all aff ect bone turnover as well. 
In addition, repair processes in healing PCa metastatic lesions may also cause raised levels of 
these markers, thereby decreasing specifi city.
First, the markers in bone formation will be discussed, followed by the markers in bone 
resorption. Finally, 2 additional markers of bone metabolism in PCa will be considered.
4.1 Markers of bone formation
Th e major structural protein in bone is type I collagen. Th is is synthesized by osteoblasts as a 
pro-collagen and during posttranslational modifi cation in the extracellular space, the amino- 
(PINP) and carboxyl- (PICP) propeptides are removed. Bone-specifi c alkaline phosphatase 
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(bAP) is associated with osteoblast maturation and activity and seems to be important in 
the initiation of new bone mineralization. PINP, PICP and bAP could therefore function as 
markers of bone formation. Serum levels of all three were elevated in metastatic PCa patients 
compared to non-metastatic ones [49-51].
4.2 Markers of bone resorption
Type I collagen of bone is strengthened by specifi c molecular cross-links that provide rigidity, 
i.e. pyridinium, pyridinoline and deoxypyridinoline (DPD). When collagen is broken down 
during bone resorption, these collagen cross-links cannot be degraded and are therefore 
released into the blood and subsequently excreted in urine. Fift y to sixty percent are bound 
to type I collagen fragments in the form of cross-linked amino- (NTX) or carboxyl- (CTX) 
terminal telopeptides. Pyridinoline cross-linked carboxy-terminal telopeptide (ICTP) is 
another degradation product of type 1 collagen.
DPD, NTX, CTX and ICTP could therefore function as markers of bone resorption. 
Urine levels of DPD [52] and α-CTX (i.e. the α-isomerised form of CTX) [50] were elevated 
in metastatic PCa patients compared to non-metastatic ones. Th e same was true for serum 
levels of NTX [50], β-CTX (i.e. the β-isomerised form of CTX) [50] and ICTP [49,50].
4.3 Bone morphogenetic protein 6
As members of the transforming growth factor-β superfamily, bone morphogenetic 
proteins have the capacity to induce bone formation. Th erefore, one of these proteins, bone 
morphogenetic protein 6 (BMP-6), has been studied for its role in PCa bone metastasis.
Detection of BMP-6 in prostatectomy samples correlated with bone metastasis [53]. In 
addition, the majority of PCa bone metastases expressed BMP-6 [54]. A prerequisite for 
investigating the use of BMP-6 as a prognostic serum PCa marker is a sensitive serum test. 
However, to date such a test has not been described in literature.
4.4 Osteoprotegerin
Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily. As 
an inhibitor of osteoclast maturation, it is involved in the regulation of bone resorption. 
In addition, it acts as a survival factor for PCa cells in vitro by inhibiting apoptosis [55]. 
Th erefore, OPG has been studied for its role in PCa bone metastasis.
OPG serum levels were elevated in metastatic PCa patients compared to non-metastatic 
ones. Furthermore, these levels correlated with biochemical and/or clinical relapse in 
metastatic PCa patients, receiving androgen ablative treatment [55], and OPG was an 
independent prognostic factor for PCa mortality [49].
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Th e serum and urine PCa markers discussed in this article represent a selection based on 
expert opinion. No attempt was made to include all PCa markers that were either investigated 
in the past or are being investigated at the moment. Th e fi eld of PCa marker research is 
vast. Th is is illustrated by a recent review, in which Tricoli et al. examined the current status 
of molecular markers in PCa and cited as many as 91 diff erent potential markers [16]. 
Moreover, the fi eld of PCa marker research is continuously changing. Th erefore, an overview 
is by defi nition incomplete and outdated. In an attempt to keep our information as up to 
date as possible, we performed a PubMed search on April 1st 2005. We used the search term 
‘prostate cancer’ combined with either ‘serum marker’ or ‘urine marker’ and applied the 
following limits: ‘Field: Title/Abstract, Limits: 2 Years, English, Cancer’. Th is resulted in 99 
and 12 hits respectively. Excluding all reviews, we found articles on 22 additional serum and 
urine PCa markers. Table II displays 12 additional markers in the four categories discussed 
in this article. Table III displays 10 additional markers in diff erent categories, as all intra- and 
extracellular mechanisms that are known to be involved in tumor growth and metastasis, are 
being investigated for the identifi cation of new PCa markers.
Th e P-Mark project
P-Mark is one of three complementary projects the European Community has selected for 
strengthening cancer research in the biomedical sciences within the 2002 Sixth Framework 
Programme for Research and Technological Development. Th e other two projects are 
PRIMA (PRrostate cancer Integral Management Approach), which is directed at the genomic 
and proteomic characterization of metabolic pathways specifi c in PCa, and GIANT (Gene 
therapy: an Integrated Approach for Neoplastic Treatment), which aims at the development 
of viral and non-viral vectors for the targeted treatment of PCa. P-Mark (http://www.p-
mark.org) is a specifi c targeted research project, offi  cially titled: ‘a validation of recently 
developed diagnostic and prognostic markers and identifi cation of novel markers for PCa 
using European databases’. For a period of 3 years, better diagnostic and prognostic PCa 
markers will be investigated, by both the identifi cation and evaluation of novel markers as 
well as the evaluation and validation of recently developed promising markers. In summary, 
a serum and urine biorepository, which includes matching tissue and clinical data from well-
characterised PCa patients from several centres, will be constructed and managed.
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Table II. Additional serum and urine prostate cancer markers
Marker Sample type Purpose Reference(s)
Prostate-specifi c proteins
Intracellular prostate-specifi c antigen in peripheral macrophages Blood Diagnosis [56,57]
Human kallikrein 11 Serum Diagnosis [58]
Progastrin-releasing peptide Serum Prognosis [59]
Genetic variations in prostate cancer
Androgen receptor gene N-terminal CAG repeat length polymorphism Blood Prognosis [60]
Cytochrome P450 11A1 gene polymorphism Blood Prognosis [61]
8-hydroxydeoxyguanosine Urine Diagnosis [62]
Genes overexpressed in prostate cancer
Bradeion Urine Diagnosis [63]
Markers of bone metabolism
Tartrate-resistant acid phosphatase isoenzyme 5b Serum Prognosis [49,64]
Total alkaline phosphatase Serum Prognosis [49]
Osteocalcine Serum Prognosis [49]
Bone sialoprotein Serum Prognosis [49]
Receptor activator of nuclear factor-κB ligand Serum Prognosis [49,65]
Table III. Additional serum and urine prostate cancer markers
Marker Sample type Purpose Reference(s)
Angiogenesis and tumor invasion
Vascular endothelial growth factor Platelet-poor plasma Prognosis [66]
Basic fi broblast growth factor Platelet-poor plasma and urine Prognosis [66]
Matrix metalloproteinase 2 and 9 Serum Prognosis [67]
Endocrine signal transduction
Testosterone Serum Prognosis [60,68]
Insulin-like growth factor I Serum Diagnosis [69]
Signal transduction
Caveolin-1 Serum Diagnosis [70]
Isoform of apolipoprotein A-II Serum Diagnosis [71]
50.8-kDa protein Serum Diagnosis [72]
Calgranulin B Urine Diagnosis [73]
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Innovative mass spectrometry tools, which will be described later, will generate protein 
and/or peptide profi les from the serum and urine samples in these biorepositories. Analysis 
of the presence of PCa-related peaks in these profi les by bioinformatics will identify novel 
peptide or protein markers. Antibody-based immunoassays for these markers will be 
developed. Th ose markers that meet the criteria defi ned in Table IV will be evaluated for their 
clinical importance using these assays. Recently developed promising markers (i.e. PCA3, 
BMP-6, OPG, nicked PSA, hK2 and the CYP3A5*3 polymorphism) will be evaluated for 
their clinical value, using the same biorepositories. Essential is the fact that a highly sensitive 
assay for the measurement of serum and plasma levels of BMP-6 has been developed at the 
site of one of the P-Mark project participants (i.e. the University of Turku in Turku, Finland) 
(unpublished data) (Table I). Using this assay, BMP-6 can be investigated for its use as a 
prognostic serum PCa marker. Th ose markers that prove their clinical value during evaluation 
will be validated in a mono- or multi-centre setting and on a sample set derived from 2 large, 
European PCa studies, i.e. the European randomized study of screening for prostate cancer 
(ERSPC) and the prostate testing for cancer and treatment (ProtecT) study. Th e ERSPC 
analyzes the eff ect of early detection of PCa on mortality and quality of life in over 200,000 
European men [74] and the ProtecT study is a three-arm randomised trial of treatment for 
localised PCa, preceded by a programme of case-fi nding, involving over 100,000 men in the 
United Kingdom [75]. Eventually, the markers arising from this project will be used for the 
identifi cation of special risk groups in the general population. A schematic overview of the 
P-Mark project design is presented in Figure 2.
Table IV. Th e 5 marker criteria in the P-Mark project
1. Improved sensitivity and specifi city over current markers for diagnosis or prognosis
2. Indicative for early detection, overtreatment, risk for progression or therapy resistance
3. Clinical relevant target in relation to tumor biology
4. Reliable and cost-effi  ciently determinable in non-invasively obtained specimens
5. Stable component in specimen 
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Establishment of serum
and urine biorepository
Discovery and evaluation of 
novel prostate cancer markers
Identification of 
risk groups
Evaluation of recently 
developed promising 
prostate cancer markers 
Clinical implementation 
of recently developed 
promising prostate 
cancer markers
1
1
1 2 3 4 5 6
2 3 4 5 6 81 2 3 4 6 8 9
1
Coordinator
Partner
5 6 7 8 9
Two large, 
European 
prostate 
cancer studies
Expected results:
– Newly validated prostate cancer markers
– Novel prostate cancer markers ready for validation
– Identification of risk groups in the European population
– Guidelines for prostate cancer detection and therapy
Figure 2. A schematic overview of the P-Mark project design. Th e numbers refer to the diff erent 
participants as follows: 1 Erasmus MC, Rotterdam, Th e Netherlands; 2 Lund University, Malmö, 
Sweden; 3 Radboud University Nijmegen Medical Centre, Nijmegen, Th e Netherlands; 4 University 
of Sheffi  eld, Sheffi  eld, United Kingdom; 5 University of Helsinki, Helsinki, Finland; 6 University 
of Turku, Turku, Finland; 7 University of Groningen, Groningen, Th e Netherlands; 8 Innotrac 
Diagnostics Oy, Turku, Finland; 9 CanAg Diagnostics AB, Göteborg, Sweden.
Novel tools: mass spectrometry
We will now discuss the innovative mass spectrometry tools used in the P-Mark project 
to fi nd novel PCa markers. As mentioned earlier, these tools will generate protein and/or 
peptide profi les from serum and urine samples.
Mass spectrometry (MS) is based on producing, separating, and detecting ions in the gas 
phase (Figure 3, the numbers in the text below refer to the numbers in the fi gure). Th erefore, 
to analyze proteins and/or peptides via MS, they should be ionized and volatilized. As 
heating causes degradation, this has long been a problem. Two Nobel Prize winning 
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techniques (2002, John B. Fenn and Koichi Tanaka) have overcome this diffi  culty: matrix-
assisted laser desorption ionization (MALDI) and electrospray ionization (ESI). MALDI 
sublimates and ionizes the protein and/or peptide analytes out of a dry, crystalline matrix via 
laser pulses (Figure 3: 1). Th e matrix serves to minimize sample damage from the laser beam 
by absorbing its energy [76]. ESI involves preparing small electrically charged droplets from 
the analytes dissolved in solvent (Figure 3: 2). Evaporation of the solvent reduces the size 
of the droplets, thereby increasing the repulsive forces within. As the droplets get smaller, 
this causes them to disintegrate, forming even smaller droplets that will undergo the same 
process and so on, eventually releasing ionized sample molecules in the gas phase [77]. ESI 
is oft en preceded by nanofl ow liquid chromatography (nanoLC) (Figure 3: 3). Th is is a 
nanotechnology used to separate protein and/or peptide mixtures based on diff erences in 
their relative affi  nities for a mobile and a stationary phase, in which the fl ow can be very low 
(i.e. 100 nl per minute). NanoLC can therefore serve to separate a sample solution into its 
diff erent components prior to ESI and mass spectrometry analysis. In the P-Mark project 
both MALDI and nanoLC, the latter via ESI, will be combined with Fourier transform 
ion cyclotron resonance mass spectrometry (FT-MS) (Figure 3: 4). Both methods will be 
preceded by a prefractionation procedure based on molecular size (e.g. ultrafi ltration, size 
exclusion or monolithic chromatography or restricted access chromatography), with or 
without prior proteolytic digestion. Th is is done to increase resolution (i.e. the separation 
of proteins and/or peptides). A possible disadvantage is the loss of PCa markers by this 
preceding procedure.
FT-MS is a mass spectrometry technique that is based on an ion’s motion in a magnetic 
fi eld (Figure 3: 5). Th e ionized, volatile, analyte molecules are brought into a magnetic fi eld 
were they move in a circular orbit in a two-dimensional plane. Aft er excitation these orbiting 
ions produce measurable sinusoidal currents and as ions of diff erent mass create diff erent 
signals, the overall signal is a representation of the mixture of ions present (Figure 3: 6). 
Using the mathematics of the Fourier transform method, it is possible to unravel this signal 
and translate it into a complete mass spectrum [78]. Th e third analytical method used in 
the project is surface-enhanced laser desorption ionization time-of-fl ight mass spectrometry 
(SELDI-TOF MS). Th is technique is a combination of chromatography and mass spectro-
metry, overcoming the need for elusive sample preparation. A serum or urine sample is applied 
directly to a surface with defi ned chemical (e.g. hydrophilic, hydrophobic, anionic or cationic) 
or biochemical characteristics (e.g. receptors, enzymes, ligands or antibodies) (Figure 3: 7). 
Th e unbound molecules are washed away and the adherent protein and/or peptide analytes 
are ionized. A laser blasts off  (desorbs) the ions (Figure 3: 8), which are protected by an 
Innovations in serum and urine markers in prostate cancer
– 31 –
C
ha
pt
er2
energy-absorbing compound attached directly to the probe surface, launching them to fl y 
towards an oppositely charged electrode (Figure 3: 9). Th e time it takes for a launched ion 
to then reach a detector is a measure for its mass (i.e. small ions travel faster than larger ones), 
thereby resulting in a MS profi le of the protein and/or peptide analytes [79]. Discriminating 
PCa using these profi les may be possible [80], but thus far direct identifi cation and isolation 
of the protein or peptide underlying the disease-associated peak is not.
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Figure 3. Protein and/or peptide profi les from serum and urine samples will be generated using 
innovative mass spectrometry tools. A detailed description of these techniques is provided in the text.
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Conclusions
Th ere are large numbers of markers showing promise to overcome the limitations of PSA. 
Eventually, these markers should be able to increase the specifi city in diagnosis, diff erentiate 
between harmless and aggressive disease and identify progression towards androgen 
independence at an early stage.
In the P-Mark project, several recently developed, promising markers will be evaluated, 
validated and used for the identifi cation of special risk groups in the general population. In 
addition, novel markers will be identifi ed by diff erent mass spectrometry techniques.
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Abstract
Purpose
To improve the specifi city in prostate cancer diagnosis and to prevent unnecessary prostate 
biopsies, especially in the serum PSA ‘gray zone’ between 3 and 15 ng/ml, the implementation 
of prostate cancer-specifi c markers is urgently needed. Th e recently discovered PCA3 is such 
a promising prostate cancer marker. In a previous single institution study, the PCA3 urine 
test clearly proved to be of diagnostic value. Th erefore, the diagnostic performance of the 
PCA3 urine test was validated in a multicenter study.
Experimental design
Th e fi rst voided urine aft er digital rectal examination was collected from a total of 583 men 
with serum PSA levels between 3 and 15 ng/ml who were to undergo prostate biopsies. We 
determined the PCA3 score in these samples and correlated the results with the results of 
the prostate biopsies.
Results
534 men (92%) had an informative sample. Th e area under the receiver operating characteristic 
curve, a measure of the diagnostic accuracy of a test, was 0.66 for the PCA3 urine test and 
0.57 for serum PSA. Th e sensitivity for the PCA3 urine test was 65%, the specifi city was 66% 
(versus 47% for serum PSA) and the negative predictive value was 80%.
Conclusions
In this multicenter study we validated the diagnostic performance of the PCA3 urine test in 
the largest group studied to date using a PCA3 gene-based test. Th is study shows that the 
PCA3 urine test, when used as a refl ex test, can improve the specifi city in prostate cancer 
diagnosis and could prevent many unnecessary prostate biopsies.
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Introduction
Nowadays, prostate cancer (PCa) is by far the most common cancer in men in the United 
States of America (excluding basal and squamous cell skin cancers and in situ carcinoma 
except urinary bladder). In 2006, PCa will be diagnosed in approximately 234,460 American 
men and 27,350 American men will die of this disease [1]. In Europe, in 2002 an estimated 
225,227 men were newly diagnosed with PCa and about 83,066 died from this disease. For 
Th e Netherlands, these numbers were 7,112 and 2,529 respectively (http://www-dep.iarc.
fr) [2].
Serum prostate-specifi c antigen (PSA) is regarded as the standard diagnostic PCa marker. 
PCa awareness, leading to widespread use of PSA testing has led to a stage shift , i.e. a lower 
tumor stage and grade at the time of diagnosis. However, PSA is not cancer-specifi c, resulting 
in a high negative biopsy rate. Moreover, its use is associated with certain drawbacks, e.g., the 
diagnosis of clinically irrelevant tumors (i.e. overdiagnosis) and potentially overtreatment 
[3].
As a result, there is an urgent need for PCa-specifi c markers that can improve the 
specifi city in PCa diagnosis and can prevent unnecessary prostate biopsies, especially in the 
serum PSA ‘gray zone’ between 3 and 15 ng/ml, in which nowadays many newly diagnosed 
men are.
PCA3 is a prostate-specifi c non-coding mRNA which is highly overexpressed in more 
than 95% of primary PCa specimens and PCa metastases [4,5]. Hessels et al. found that 
the median up-regulation of PCA3 in PCa tissue compared with normal prostate tissue 
was 66-fold [6]. Moreover, a median 11-fold up-regulation was found in prostate tissues 
containing less than 10% of PCa cells. As PCA3 is a non-coding mRNA, a dual time resolved 
fl uorescence (TRF) -based RT-PCR assay was developed to identify it as a diagnostic 
PCa marker in prostate cells in urinary sediments aft er digital rectal examination (DRE). 
Th is second generation test showed a negative predictive value of 90% in a population of 
men, admitted for prostate biopsies based on a serum PSA value > 3 ng/ml [6]. Th erefore, 
PCA3 clearly showed to have diagnostic value and great potential in reducing the number 
of unnecessary biopsies. Using the fi rst generation uPM3™ test, a qualitative nucleic acid 
sequence-based amplifi cation (NASBA) technology, two independent studies confi rmed 
these results [7,8]. Earlier this year, Groskopf et al. introduced the quantitative automated 
probe transcription-mediated amplifi cation (APTIMA®) PCA3 urine test, a third generation 
PCA3 assay, which uses transcription-mediated amplifi cation (TMA): a RNA transcription 
amplifi cation system using RNA polymerase and reverse transcriptase to drive the isothermal 
reaction that allows the reaction to be carried out in a single tube format [9].
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Because of the promising results of our previous single institution study [6], the aim of 
this study was to validate the diagnostic performance of the TRF-based PCA3 urine test in a 
multicenter setting. Th erefore, we correlated the PCA3 score in urinary sediments aft er DRE 
with the presence of PCa in subsequent prostate biopsies. Here, the results of the TRF-based 
PCA3 urine test are reported in a group of 583 men, the largest group studied to date using 
a PCA3 gene-based test.
Materials and Methods
In the urological outpatient clinics of fi ve Dutch hospitals (one university hospital and four 
community hospitals) the fi rst voided urine aft er DRE was collected from a total of 583 men 
with serum PSA levels between 3 and 15 ng/ml (extremes included) who were to undergo 
ultrasound-guided, transrectal, prostate biopsies as a result of local management.
Beforehand all men had received study information and had signed their informed 
consent.
As part of standard clinical practice, both serum PSA and the fraction of free serum PSA 
had already been determined in most men.
All other samples and data were collected prospectively.
Th e DRE was performed according to a standard protocol: by applying fi rm pressure 
to the prostate (enough to depress the surface) from the base to apex and from the lateral 
to the median line for each lobe. Th e men were asked to void and the fi rst voided urine was 
collected.
Following urine collection, the urologist measured the prostate by transrectal ultra-
sonography and performed the prostate biopsy according to a standard protocol (at least 
3 biopsies from the left  peripheral zone, at least 3 biopsies from the right peripheral zone, 
1 biopsy from the left  transition zone and 1 biopsy from the right transition zone, plus 
additional biopsies from other areas suspicious for PCa when present). All biopsy cores were 
treated lege artis and examined for the presence of PCa.
Th e fi rst voided urine aft er DRE was collected in a coded container with 4 ml 0.5 M 
EDTA. All samples from the four community hospitals were immediately cooled to 4 °C 
and were mailed in batches with cold packs to the laboratory in the university hospital. Th e 
samples were processed within 48 hours aft er the sample was acquired to guarantee good 
sample quality. Th e samples taken at the university hospital were processed within one hour. 
Upon centrifugation at 4 °C and 700 g for 10 minutes, urinary sediments were obtained. 
Th e PCA3 urine test; a Dutch multicenter validation
– 43 –
C
ha
pt
er3
Th ese urinary sediments were washed twice with ice-cold PBS (at 4 °C and 700 g for 10 
minutes), snap-frozen in liquid nitrogen, and stored at -70 °C. Th e urinary sediments were 
spiked with 20 μg of E. coli tRNA as a carrier (Roche Diagnostics, Almere, Th e Netherlands). 
Total RNA was extracted from these urinary sediments, using TRIzol® Reagent (Invitrogen, 
Breda, Th e Netherlands).
To correct for the number of prostate cells present, the PSA transcripts were quantitatively 
determined in the urinary sediments, using the dual TRF-based, quantitative RT-PCR 
protocol for PSA described by Ylikoski et al. [10, 11] and modifi ed by Hessels et al. [6].
Similarly, the PCA3 transcripts were quantitatively determined in the same urinary 
sediments, using a dual TRF-based, quantitative RT-PCR protocol for PCA3.
Briefl y, in vitro transcribed PCA3 mRNA and internal standard (IS) PCA3 mRNA 
were used as templates for cDNA synthesis using the 1st-strand cDNA synthesis Kit 
(Amersham, Buckinghamshire, United Kingdom). PCA3 and IS-PCA3 mRNA were 
diluted in 0.2 mg/ml E. coli tRNA (Roche Diagnostics), which was used as carrier RNA. 
For the preparation of a calibration curve, 5,000 copies of IS-PCA3 mRNA were mixed 
with a variable amount (50 to 10,000,000 copies) of PCA3 mRNA. For the quantifi cation 
of PCA3 mRNA in a sample, 5,000 copies of IS-PCA3 mRNA were added to each RNA 
sample before the reverse transcriptase reaction. Th e RNA samples were heated for 10 
minutes at 65 °C followed by reverse transcription for 1 hour at 37 °C, using 0.2 mg of 
universal oligo-d(T)18 primer, 2 mM DTT and 5 ml of a Bulk 1st-strand reaction mixture 
(Amersham). For PCR amplifi cations, the following PCA3-specifi c primers were used: 
forward, 5ʹ-TGGGAAGGACCTGATGATACA-3ʹ (nucleotides 97-108 of exon 1 of the 
PCA3 cDNA, GenBank #AF103907) and reverse, 5ʹ-CCCAGGGATCTCTGTGCTT-3ʹ 
(nucleotides 459-477, spanning exons 3 and 4 of the PCA3 cDNA). Aft er 35 cycles of 
PCR, the amplifi cation products were quantifi ed by the TRF-based hybridization assays 
on streptavidin-coated microtitration wells. For the target-specifi c detection a PCA3 
detection probe (30 pg/ml) labeled with Eu3+ and an IS-PCA3 detection probe (30 pg/ml) 
labeled with Tb3+ were used. Th e amount of PCA3 mRNA in the sample was calculated by 
comparing the PCA3 / IS-PCA3 fl uorescence ratio in the sample with that of the samples 
in the calibration curve.
Th e ratio PCA3 / PSA mRNA was then calculated by dividing the number of PCA3 
mRNA copies by the number of PSA mRNA copies obtained in a given sample. Th e PCA3 
score was defi ned as the ratio PCA3 / PSA mRNA x1,000.
Data were analyzed using the Statistical Package for the Social Sciences (SPSS, Chicago, 
IL, USA) version 12.0.1 for Microsoft  Windows.
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To test for diff erences in PCA3 score between men with a negative and men with a 
positive biopsy result, we used the two-tailed Mann-Whitney U test.
We also used the two-tailed Mann-Whitney U test to test for diff erences in PCA3 
score between the biopsy-negative university hospital population and the biopsy-negative 
community hospital population, as well as between the biopsy-positive university hospital 
population and the biopsy-positive community hospital population.
A p value < 0.05 was considered signifi cant.
Results
Th e total number of urine samples that could be analyzed successfully (i.e. was positive for 
PSA mRNA expression) was 534 out of the 583 that were collected. Th erefore, the analytical 
performance of the PCA3 urine test was (534 / 583 =) 92% overall; (295 / 312 =) 95% in 
the university hospital and (239 / 271 =) 88% in the community hospitals.
Th e mean age at the time of biopsy of the 534 men in the study population was (mean 
± SD) 64.3 ± 7.2 years; the mean serum PSA value was 7.49 ± 2.93 ng/ml; the mean fraction 
of free serum PSA (determined in 173 / 534 = 32%) was 0.19 ± 0.11; and the mean total 
prostate volume (measured in 250 / 534 = 47%) was 48.2 ± 28.4 ml.
Of the 534 men who yielded informative specimens 174 (33%) had PCa in their biopsies 
and the remaining had negative biopsies.
Th e PCA3 scores obtained for both subject groups were summarized in a boxplot (Figure 
1). Th e median score for men with a negative biopsy result was 24 (range 0 – 1862), the 
median score for men with a positive biopsy result was 90 (range 0 – 4088). Th e diff erence 
between both groups was highly signifi cant (p = 1.10-9).
Th e diagnostic effi  cacy of the PCA3 test is visualized by a receiver operating characteristic 
(ROC) curve in which the test variable was the PCA3 score and the state variable the biopsy 
result (Figure 2). In the absence of an arbitrary cut-off  value, we determined a cut-off  value 
of 58 for PCa diagnosis based on this ROC curve. A lower cut-off  value would not have 
increased the sensitivity of the test, but would have only resulted in a loss of specifi city. A 
similar procedure was described earlier [6]. Th e area under the curve (AUC), a measure of 
the diagnostic accuracy of a test, was 0.66 (95% confi dence interval (CI) 0.61 – 0.71) for the 
PCA3 test.
Th e diagnostic value of the serum PSA test is also visualized (Figure 2), for serum PSA 
the AUC was 0.57 (95% CI 0.52 – 0.63).
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Figure 1. Boxplot (also known as a ‘box-and-whisker diagram’) showing the PCA3 scores in urinary 
sediments aft er digital rectal examination for both men with a negative (on the left ) and men with a 
positive biopsy result (on the right). Th e median value (thick black horizontal line), outliers (open 
circles) and extremes (stars) are shown. Th e box length is the interquartile range and the ‘whiskers’ 
extend to 1.5 times this distance. (PSA = prostate-specifi c antigen)
For the serum free PSA test the AUC was 0.58 (95% CI 0.48 – 0.68) (not shown).
Using this cut-off  of 58 for the detection of PCa by the PCA3 urine test, we calculated 
the sensitivity, specifi city and the negative predictive value. Th e sensitivity was 65%, the 
specifi city was 66% and the negative predictive value was 80% (Table I). For the serum PSA 
test at the same sensitivity (65%), the specifi city was 47% (Figure 2).
A higher PCA3 score also correlated with a higher probability of a positive biopsy result 
(Figure 3).
Th e diagnostic performance of the TRF-based PCA3 urine test was compared between 
the university hospital population and the community hospitals population.
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Figure 2. Receiver operating characteristic curve for the PCA3 score (black line) in urinary 
sediments aft er digital rectal examination and serum PSA (dotted black line) in the detection 
of prostate cancer, using biopsy histopathology as standard of reference. Th e vertical and 
horizontal dotted grey lines indicate the determined cut-off  value of 58. (PSA = prostate-
specifi c antigen)
Table I. TRF-based PCA3 urine test results versus biopsy results
Prostate cancer No malignancy Total
PCA3 score > 58 113 122 235
PCA3 score < 58  61 238 299
Total 174 360 534
In the university hospital the median PCA3 score in men with a negative biopsy was 
11 (range 0 – 1,779), the median PCA3 score in men with a positive biopsy was 73 (range 
0 – 1,432). Th e AUC for the PCA3 test was 0.65 (95% CI 0.58 – 0.72). Using the cut-off  
value of 58 (determined in the total multicenter population), the sensitivity for the detection 
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of PCa of the PCA3 urine test in the university hospital population was 59%, the specifi city 
was 74% and the negative predictive value was 79%.
Th e AUC for the serum PSA test was 0.55 (95% CI 0.48 – 0.62).
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Figure 3. Diagram of the probability of a positive biopsy result for diff erent ranges of the PCA3 score. 
Both the number of men with prostate cancer and the total number of men per range are shown at the 
bottom.
In the four community hospitals together the median PCA3 score in men with a negative 
biopsy was 39 (range 0 – 1,862), the median PCA3 score in men with a positive biopsy was 
107 (range 0 – 4,088) and the AUC for the PCA3 test was 0.67 (95% CI 0.60 – 0.75). Again 
the cut-off  value of 58 was used, and in the community hospital population the sensitivity 
was 72%, the specifi city was 56% and the negative predictive value was 80%.
Th e AUC for the serum PSA test was 0.61 (95% CI 0.53 – 0.68).
Th e diff erences in PCA3 score between the biopsy-negative university hospital population 
and the biopsy-negative community hospital population (p < 0.001 ), as well as between the 
biopsy-positive university hospital population and the biopsy-positive community hospital 
population (p < 0.01 ) were signifi cant.
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Discussion
Because of the promising results of our previous single institution study, the aim of this study 
was to validate the diagnostic performance of the TRF-based PCA3 urine test in a multicenter 
setting. Th erefore, the PCA3 score in urinary sediments aft er DRE was correlated with the 
presence of PCa in subsequent prostate biopsies.
In our previous study the sensitivity for the detection of PCa by the PCA3 test in urine 
was 67%, the specifi city was 83% and the negative predictive value was 90% [6]. In this study, 
these values were 65%, 66% and 80% respectively.
Th e high negative predictive value in particular suggests that the PCA3 test can be used 
to reduce the number of unnecessary biopsies.
We have summarized the results of all reports on PCA3 gene-based urine testing, including 
our present study (Table II). Most test performance characteristics in this multicenter study 
are somewhat lower than in the other studies, in particular when compared with our previous 
study. A possible explanation for this could be the fact that 55% of our study population 
consisted of mostly prescreened men who were referred to a university hospital. In this 
population the AUC for the PCA3 urine test was lower than in the community hospitals 
population and consequently brought down the overall test performance. Noteworthy is the 
fact that in the university hospital population the PCA3 urine test still performed much 
better than the serum PSA test since the latter was no better than the fl ip of a coin.
Formally, it was statistically incorrect to calculate the sensitivity and specifi city for the 
serum PSA test, because a serum PSA value between 3 and 15 ng/ml was a requirement to 
enter the study. However, for reason of comparison we showed that at an equal sensitivity of 
65%, the specifi city for the serum PSA test was only 47%, compared to 66% for the PCA3 
urine test. Th is suggests that the PCA3 test can be used to improve the specifi city in PCa 
diagnosis.
92% overall analytical performance indicates that the transport and processing of the 
urine samples in a multicenter setting is feasible. Th e diff erence in analytical performance 
of the PCA3 urine test between the university hospital (95%) and the community hospitals 
(88%), could not be attributed to RNA degradation that could have occurred during 
transport, because the median copy numbers of PCA3 and PSA mRNA in the samples from 
the community hospitals were higher when compared with the samples from the university 
hospital (data not shown).
Th e median PCA3 scores in both the biopsy-negative and the biopsy-positive groups 
of the community hospitals were signifi cantly higher than the scores in both groups of the 
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university hospital respectively. As a result, when using the cut-off  value that was determined 
in the total multicenter study population, the sensitivity of the TRF-based PCA3 urine test 
was higher (72%) for the study population of the community hospitals when compared with 
the sensitivity for the study population of the university hospital (59%). Consequently, the 
specifi city was lower (56% versus 74%).
Th e diff erences observed were not attributable to RNA degradation during transport. 
A possible explanation is the diff erence in study population between the university and the 
community hospitals. A clue in this direction is the fact that the serum PSA test performed 
better in the community hospitals study population, with an AUC of 0.61 instead of 0.55 for 
the university hospital study population. Th e median serum PSA value was also signifi cantly 
higher in the community hospitals study population (data not shown). Th erefore, the 
university hospital study population could have been more prescreened. 
Th e variance in the median value of the PCA3 score between diff erent study populations 
and the fact that a higher score correlated with a higher probability of a positive biopsy 
result, also suggests that it would be better to use the result of the PCA3 urine test as a 
continuous risk variable instead of strictly applying a certain cut-off  value, resulting in a test 
with a dichotomous result.
In the group of men with a negative biopsy outcome there were several men with a high 
PCA3 score (the outliers: 25 / 360 = 7% and extremes: 18 / 360 = 5% in Figure 1). We 
speculate that in this group there is a substantial number of men who actually have PCa, but 
in whom it was missed on biopsy. It is well known that some 10-20% of men with a previous 
negative biopsy will be diagnosed with PCa upon repeat biopsy [12]. Moreover, several men 
included in the study published by Hessels et al. [6] who had negative biopsies but a positive 
PCA3 urine test were shown to have PCa upon repeated biopsies (unpublished data). Th e 
follow-up data of our study population will have to show if indeed the PCA3 urine test was 
able to ‘predict’ the presence of PCa.
In conclusion, this Dutch multicenter study showed that to improve the specifi city in 
PCa diagnosis and reduce the number of unnecessary biopsies, the TRF-based PCA3 urine 
test is of value as a refl ex-test in the serum PSA ‘gray zone’ between 3 and 15 ng/ml.
At a cut-off  value of 58, the sensitivity for the detection of PCa by the PCA3 test in urine 
was 65%, the specifi city was 66% (compared to 47% for the serum PSA test) and the negative 
predictive value was 80%.
A higher PCA3 score correlated with a higher probability of a positive biopsy result.
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Abstract
Background
Th e PCA3 test on urine can improve specifi city in prostate cancer diagnosis and could 
prevent unnecessary prostate biopsies. In this study we evaluated the PCA3 test on prostatic 
fl uid and compared this with the PCA3 test on urine in a clinical research setting.
Methods
Prostatic fl uid and urine samples from 67 men were collected following digital rectal 
examination. Th e sediments were analyzed using the quantitative APTIMA® PCA3 test. Th e 
results were compared with prostate biopsy results.
Results
Using a PCA3 score of 66 as a cut-off  value, the test on prostatic fl uid had 65% sensitivity 
for the detection of prostate cancer, 82% specifi city and a negative predictive value of 82%. 
At a cut-off  value of 43, the test on urine had 61% sensitivity, 80% specifi city and a negative 
predictive value of 80%.
Conclusions
Th e PCA3 test can be performed on both urine and prostatic fl uid in the diagnosis of prostate 
cancer with comparable results.
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Introduction
Currently, prostate cancer (PCa) is the most common cancer in men in the United States of 
America. In 2006, PCa will be diagnosed in approximately 234,460 American men [1]. Since 
27,350 American men will die of this disease, the ‘incidence mortality ratio’ will be 8.57. Th is 
indicates that almost 7 out of 8 men with PCa will die with it and not fr om it.
In comparison, in Europe an estimated 225,227 men were newly diagnosed with PCa 
in 2002 and about 83,066 died from this disease (http://www-dep.iarc.fr) [2]. Th is trend 
poses a dilemma for the urologist and biomarkers are urgently needed to aid in the treatment 
decision.
Serum prostate-specifi c antigen (PSA) is regarded as the standard diagnostic PCa marker. 
PCa awareness, leading to widespread use of PSA testing has led to a lower tumor stage 
and grade at the time of diagnosis. However, PSA is not cancer-specifi c, resulting in a high 
negative biopsy rate. Moreover, its use is associated with certain drawbacks, e.g. the diagnosis 
of clinically irrelevant tumors (i.e. overdiagnosis) and potentially overtreatment [3].
As a result, there is an urgent need for PCa-specifi c markers that can improve the 
specifi city in PCa diagnosis and can diff erentiate between indolent and aggressive disease. 
Th erefore, new PCa markers have been identifi ed and their diagnostic potential needs to be 
assessed in body fl uids such as serum, plasma, urine and prostatic fl uid [3-13].
PCA3 is a prostate-specifi c non-coding mRNA which is highly overexpressed in more 
than 95% of primary PCa specimens and PCa metastases [14,15]. Hessels et al. found that the 
median up-regulation of PCA3 in PCa tissue compared with normal prostate tissue was 66-
fold [16]. Moreover, a median 11-fold up-regulation was found in prostate tissues containing 
less than 10% of PCa cells. As PCA3 is a non-coding mRNA, a dual time resolved fl uorescence 
(TRF) -based RT-PCR assay was developed to explore the utility of PCA3 gene expression-
based analysis to identify PCa cells in urinary sediments aft er digital rectal examination 
(DRE). Because the number of cells shed into the urine is likely to vary, we decided to use 
PSA as a normalization gene, since PSA mRNA expression is rather comparable for non 
malignant and malignant prostate cells [17]. Th is TRF-based PCA3 / PSA test yielded a 
negative predictive value of 90% in a population of men, admitted for prostate biopsies 
based on a serum PSA value > 3 ng/ml. Th is fi rst study showed that PCA3 has potential 
clinical diagnostic value and may provide for more accurate biopsy decisions [16]. Using 
the uPM3™ test which is based on a quantitative nucleic acid sequence-based amplifi cation 
(NASBA) technology also using PCA3 as a target, two independent studies confi rmed 
these results [18,19]. In 2006, Groskopf et al. introduced the quantitative automated probe 
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transcription-mediated amplifi cation (APTIMA®) PCA3 test which uses transcription-
mediated amplifi cation (TMA): a RNA transcription amplifi cation system using RNA 
polymerase and reverse transcriptase to drive the isothermal reaction that allows the reaction 
to be carried out in a single tube format [20]. Recently, Hessels et al. demonstrated that the 
results obtained with the APTIMA® PCA3 test using urinary sediments instead of whole 
urine are similar to those obtained with the TRF-based PCA3 test (Hessels et al. submitted). 
In conclusion, quantifi cation of PCA3 gene expression using three established and validated 
technology platforms yielded similar results, i.e. an improved accuracy in the early detection 
of PCa.
Th e rationale for the molecular PCA3 test on urine is as follows. Both prostate and 
PCa cells shed into the prostatic ductal system. Upon DRE cells are mobilized towards the 
prostatic urethra and upon micturition they are fl ushed out with the fi rst voided urine.
It is also known that occasionally during the DRE a patient will produce a few drops of 
prostatic fl uid from the meatus. Naturally, this fl uid should also contain prostate and PCa 
cells. Consequently, prostatic fl uid could be a suitable substrate for the PCA3 test. Upon 
micturition the cells remaining in the (prostatic) urethra will be fl ushed out with the fi rst 
voided urine.
Th us far, to our knowledge, nobody has used prostatic fl uid samples for molecular 
diagnostic testing. In this study we compared the diagnostic value of the APTIMA® PCA3 
test on prostatic fl uid with that on urine aft er DRE in 67 men who were to undergo prostate 
biopsies.
Materials and Methods
Prostatic fl uid and the fi rst voided urine aft er DRE were collected from 67 men who were 
to undergo ultrasound-guided, transrectal, prostate biopsies as a result of an elevated serum 
PSA value or an abnormal DRE. Th e DRE was performed by the same urologist (EBC) in 
all men at the outpatient clinic of a community hospital (Hospital Group Twente (Region 
Hospital Midden-Twente), Hengelo, Th e Netherlands).
Previously, all men had received study information and had signed their informed 
consent.
As part of standard clinical practice, both serum PSA and the fraction of free serum PSA 
had already been determined in most men.
All other samples and data were collected prospectively.
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Th e DRE was performed according to a standard protocol, by applying fi rm pressure to 
the prostate (enough to depress the surface) from the base to apex and from the lateral to the 
median line for each lobe. Exactly 3 strokes per lobe were performed.
Th e few drops of prostatic fl uid that were discharged upon DRE were collected in a coded 
container with 4 ml 0.5 M Ethylene Diamine Tetra Acetic acid (EDTA). Subsequently, the 
fi rst voided urine aft er DRE was collected in two additional coded containers with EDTA. 
Following urine collection, the urologist measured the prostate by transrectal 
ultrasonography and performed a standard 10 core prostate biopsy (5 on the left  and 5 on the 
right side of the prostate) consisting of 6 laterally directed biopsies and 4 medially directed 
biopsies (plus additional biopsies from other areas suspicious for PCa when present). All 
biopsy cores were treated lege artis and examined for the presence of PCa.
Th e prostatic fl uid and urine samples were immediately cooled to 4 °C and were mailed 
in batches with cold packs to our laboratory. Th e samples were processed within 48 hours 
aft er sample acquisition to guarantee good sample quality. Th ese preanalytical procedures are 
validated [16] and described as standard operating procedure in our laboratory and executed 
accordingly.
Upon centrifugation at 4 °C and 700 g for 10 minutes, prostatic fl uid and urinary 
sediments were obtained. Th ese sediments were washed twice with ice-cold, phosphate-
buff ered saline (PBS) (at 4 °C and 700 g for 10 minutes), snap-frozen in liquid nitrogen, and 
stored at -70 °C. Th e sediments were spiked with 20 μg of E. coli tRNA as a carrier (Roche 
Diagnostics). Total RNA was extracted from these prostatic fl uid and urinary sediments, 
using TRIzol® Reagent (Invitrogen).
8 μl of extracted RNA was dissolved in 2.6 ml of detergent-based stabilization buff er, 
which lyses the cells and stabilizes the RNA [20].
Th e quantitative APTIMA® PCA3 test uses the following Gen-Probe technologies: 
target capture, transcription mediated amplifi cation and a hybridization protection assay. 
Th e components for the APTIMA® PCA3 test include analyte-specifi c (PCA3 and PSA) 
target capture reagents, amplifi cation reagents, probe reagents, as well as calibrators and 
controls. Th e APTIMA® PCA3 test was run according to the protocol described earlier by 
Groskopf et al. [20]. In this assay both the amount of PCA3 mRNA and the amount of PSA 
mRNA in the sample were determined. As the amount of PSA mRNA was used to normalize 
for the amount of prostate-specifi c RNA in the samples, the ratio PCA3 / PSA mRNA was 
calculated. Th e PCA3 score was defi ned as the ratio PCA3 / PSA mRNA x1,000.
Of the two samples with copy numbers exceeding the highest calibrator one was diluted 
10x in the detergent-based stabilization buff er to bring the sample within the dynamic range 
of the assay and retested, the other 100x.
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Data were analyzed using the Statistical Package for the Social Sciences (SPSS, Chicago, 
IL, USA) version 12.0.1 for Microsoft  Windows.
To test for diff erences in PCA3 score between men with a negative and men with a 
positive biopsy result, we used the two-tailed Mann-Whitney U test. To test for diff erences 
in PCA3 score between the prostatic fl uid and urine samples in men with a negative biopsy 
result, as well as to test for diff erences in PCA3 score between the prostatic fl uid and urine 
samples in men with a positive biopsy result, we used the Wilcoxon signed-rank test. A 
p value < 0.05 was considered signifi cant.
Results
Prostatic fl uid and urine samples were collected from 67 men who were to undergo prostate 
biopsies.
Both samples from all 67 patients arrived in our laboratory cooled at 4 °C and were 
processed within 48 hours of acquisition. All samples were informative (i.e. were positive for 
PSA mRNA expression).
Th e mean age of the 67 men in the study population at the time of biopsy was 64.0 (SD 
7.2 years), the mean serum PSA value was 8.73 ng/ml (SD 6.61 ng/ml), the mean fraction 
of free serum PSA (determined in 44 / 67 = 67%) was 0.19 (SD 0.11) and the mean total 
prostate volume was 53.1 ml (SD 24.3 ml).
Of the 67 men 23 (34%) had PCa in their biopsies, the remaining had PCa-negative 
biopsies.
Th e PCA3 scores for both subject groups obtained from prostatic fl uid and urine samples 
were summarized in a boxplot (Figure 1).
In prostatic fl uid the median PCA3 score for the biopsy negative population was 18 
versus 73 for the biopsy positive population. Th e diff erence between both groups was highly 
signifi cant (p < 0.001).
In urine the median PCA3 score for the biopsy negative population was 19 versus 48 
for the biopsy positive population. Again, the diff erence between both groups was highly 
signifi cant (p = 0.006).
Th e diff erence between the prostatic fl uid and urine samples in the biopsy negative 
population was not signifi cant (p = 0.21), neither was the diff erence between both sample 
types in the biopsy positive population (p = 0.19).
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Figure 1. Boxplot (also known as a ‘box-and-whisker diagram’) showing the PCA3 scores in prostatic 
fl uid and urinary sediments aft er digital rectal examination for both men with a negative biopsy 
result (white boxes) and men with a positive biopsy result (grey boxes). Th e median value (thick 
black horizontal line), outliers (open circles) and extremes (stars) are shown. Th e box length is the 
interquartile range and the ‘whiskers’ extend to 1.5 times this distance.
Th e diagnostic accuracy of the APTIMA® PCA3 test on prostatic fl uid and urine samples 
was evaluated by a receiver operating characteristic (ROC) curve in which the test variable 
was the PCA3 score in both sample types and in which the state variable was the biopsy 
result (Figure 2). In the absence of an arbitrary cut-off  value, we determined a cut-off  value 
with high specifi city and reasonable sensitivity for the diagnosis of PCa. Based on this ROC 
curve we determined a cut-off  value of 66 in prostatic fl uid and of 43 in urine. A lower cut-
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off  value would only result in a decrease in the specifi city of the test without an increase 
in the sensitivity. A higher cut-off  value would only result in an increase in the specifi city 
of the test at the cost of a considerable decrease in the sensitivity. A similar procedure was 
described earlier [16]. Th e area under the curve (AUC), a measure of the diagnostic accuracy 
of a test, was 0.76 (95% confi dence interval (CI) 0.64 – 0.87) for the APTIMA® PCA3 test 
on prostatic fl uid and 0.70 (95% CI 0.58 – 0.83) for this test on urine.
For serum PSA the AUC was 0.66 (95% CI 0.53 – 0.79; Figure 2). For serum free PSA 
this was 0.65 (95% CI 0.45 – 0.85).
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Figure 2. Receiver operating characteristic curve for serum PSA (grey line) and for the PCA3 score 
in prostatic fl uid (top black line) and in urinary sediments (dashed black line) aft er digital rectal 
examination, in the detection of prostate cancer using biopsy histopathology as standard of reference. 
Th e two open circles indicate the determined cut-off  values of 66 for the APTIMA® PCA3 test on 
prostatic fl uid and 43 for this test on urine. (PSA = prostate-specifi c antigen)
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Based on the determined cut-off  of 66 for the detection of PCa by the APTIMA® PCA3 
test on prostatic fl uid, the sensitivity was 65%, the specifi city was 82%, the positive predictive 
value was 65% and the negative predictive value was 82% (Table I). For the serum PSA test at 
the same sensitivity (65%), the specifi city was 64% (Figure 2).
Table I. Results of the APTIMA® PCA3 test on prostatic fl uid versus the biopsy results
Prostate cancer No malignancy Total
PCA3 score > 66 15  8 23
PCA3 score < 66  8 36 44
Total 23 44 67
Based on the determined cut-off  of 43 for the detection of PCa by the APTIMA® PCA3 
test on urine, the sensitivity was 61%, the specifi city was 80%, the positive predictive value 
was 61% and the negative predictive value was 80% (Table II). For the serum PSA test at the 
same sensitivity (61%), the specifi city was 64% (Figure 2).
Table II. Results of the APTIMA® PCA3 test on urine versus the biopsy results
Prostate cancer No malignancy Total
PCA3 score > 43 14  9 23
PCA3 score < 43  9 35 44
Total 23 44 67
To compare the results of the APTIMA® PCA3 test on both sample types, the positive 
and negative test results were summarized (Table III). Using the determined cut-off  values, 
57 out of 67 men (85%) were classifi ed as either positive or negative by both tests. 18 men 
were shown to be positive for both tests of whom 12 (67%) had PCa upon biopsy. Both tests 
were found to be negative for 39 men of whom 33 (85%) had a negative biopsy result. 
However, 5 men were found to be positive for the APTIMA® PCA3 test on prostatic fl uid 
and negative for the APTIMA® PCA3 test on urine. Of these 5 men, 3 had PCa upon biopsy. 
Of the 5 men who were negative for the APTIMA® PCA3 test on prostatic fl uid and were 
found to be positive for the APTIMA® PCA3 test on urine, 2 men had PCa upon biopsy.
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Table III. Discordance analysis of the APTIMA® PCA3 test on prostatic fl uid versus on urine using 
the determined cut-off  values
PCA3 score in urine > 43 PCA3 score in urine < 43 Total
PCA3 score in prostatic fl uid > 66 18 (12 PCa)  5 (3 PCa) 23
PCA3 score in prostatic fl uid < 66  5 (2 PCa) 39 (6 PCa) 44
Total 23 44 67
Discussion
As PSA is not cancer-specifi c, the widespread use of PSA testing is associated with certain 
drawbacks, e.g. a high negative biopsy rate and the diagnosis of clinically irrelevant tumors 
(overdiagnosis) with the danger of overtreatment. As a result, there is an urgent need for 
PCa-specifi c markers that can improve the specifi city in PCa diagnosis and can diff erentiate 
between indolent and aggressive disease.
Th e APTIMA® PCA3 test on urine aft er DRE has been shown to improve specifi city in 
PCa diagnosis, [16,18-20] which could be applied to prevent unnecessary prostate biopsies. 
In this exploratory study we evaluated the APTIMA® PCA3 test on prostatic fl uid and 
compared it with the APTIMA® PCA3 test on urine in a clinical research setting.
Th e results indicate that the APTIMA® PCA3 test performs comparably on prostatic 
fl uid and on urine aft er DRE. Th e AUC was 0.76 for the APTIMA® PCA3 test on prostatic 
fl uid and at a determined cut-off  value of 66, the sensitivity for the detection of PCa was 
65%, the specifi city was 82% and the negative predictive value was 82%. Th e AUC was 0.70 
for the APTIMA® PCA3 test on urine and at a determined cut-off  value of 43, the sensitivity 
for the detection of PCa was 61%, the specifi city was 80% and the negative predictive value 
was 80%. Th ese results compare favorably with the results obtained thus far in other studies 
using PCA3 gene-based analysis (Table IV).
For reason of comparison we showed that at an equal sensitivity of either 61 or 65%, the 
specifi city for the serum PSA test was only 64%, compared to 82% for the APTIMA® PCA3 
test on prostatic fl uid and 80% for this test on urine. Th is suggests that the APTIMA® PCA3 
test on either sample type can be used to overcome the current problems with PSA testing, 
by improving specifi city in PCa diagnosis to reduce the number of unnecessary biopsies and 
thereby the number of cancers detected serendipitously.
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Table IV. Th e performance in prostate cancer diagnosis of PCA3 gene-based analysis following digital 
rectal examination
PCA3 
test method
Sample type Sensitivity Specifi city Negative 
predictive value
Area under the 
receiver operating 
characteristic curve
Reference
TRF-based Urine 67% 83% 90% 0.72 [16]
uPM3™ Urine 66% 89% 84% 0.86 [18]
uPM3™ Urine 82% 76% 87% 0.87 [19]
APTIMA® Urine 69% 79% 89% 0.75 [20]
APTIMA® Urine 61% 80% 80% 0.70 Th is study
APTIMA® Prostatic fl uid 65% 82% 82% 0.76 Th is study
Th e diff erences between both sample types can be subdivided according to category. In 
the biopsy negative population there was hardly any diff erence in the median PCA3 score 
between the prostatic fl uid and urine samples (18 versus 19). However, in men with PCa 
there was a diff erence (although not signifi cant) in the median PCA3 score between the 
prostatic fl uid and urine samples (73 versus 48). Th is diff erence was not caused by a higher 
amount of PCA3 mRNA in the prostatic fl uid samples, but by a median 1.4-fold increase in 
the amount of PSA mRNA in the urine samples compared with the prostatic fl uid samples 
(data not shown). Th is may indicate that in urine samples the relative fraction of non-
malignant prostate epithelial cells is higher. Moreover, the levels of PSA mRNA in the urine 
samples of men with PCa showed a signifi cant 2.2-fold increase over the amount of PSA 
mRNA in the urine samples of men with negative biopsies (data not shown). Th is might be 
a mere refl ection of increased cellularity in cancer specimens.
In addition, there is no obvious explanation for the discordance between the results of 
the APTIMA® PCA3 test on both sample types as seen in 10 men (of whom 5 had PCa upon 
biopsy). An explanation could be that in cases in which the prostatic fl uid sample tested 
positive and the urine sample did not, the prostatic fl uid sample contained the majority of 
the mobilized cells with PCA3 overexpression, i.e. PCa cells, leaving only a minor fraction 
for the urine sample. Which would result in a higher PCA3 score in the prostatic fl uid 
sample. Vice versa, in cases in which the urine sample tested positive and the prostatic fl uid 
sample did not, the prostatic fl uid sample could have contained only a minor fraction of the 
mobilized cells with PCA3 overexpression, leaving the majority for the urine sample. Th is 
would result in a lower PCA3 score in the prostatic fl uid sample.
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In this study we used the sediments of prostatic fl uid and urine samples for the APTIMA® 
PCA3 test instead of whole urine as was described by Groskopf et al. [20]. A possible advantage 
of using the sediment of a urine sample may be that the size of the sample is increased and 
that the clinical correlation is linked to cells and cell fragments in the sediment. Th e test on 
whole urine only analyzes 2 ml of the total sample. In contrast, analyzing the sediment is 
equal to analyzing all the cells in the whole sample, as these are concentrated in the sediment. 
Our results indicate that the analysis of prostatic fl uid sediments is feasible and provides 
comparable clinical utility to urine specimens. A combination of the two specimens may be 
expected to yield higher sensitivity and specifi city.
Other PCa markers in prostatic fl uid
To our knowledge, thus far only fi ve PCa markers have been investigated in prostatic fl uid: 
ornithine decarboxylase (ODC) [7], free insulin-like growth factor-1 (IGF-1) [9], telomerase 
activity/expression [4,11,12], hypermethylation of the π-class glutathione S-transferase 1 
(GSTP 1) promoter [4] and dipeptidylpeptidase IV (DPIV) [13].
Most studies however, were hampered by a limited sample size [7,12] and/or studied a 
case mix of men (with and without PCa) instead of the standard clinical population in which 
PCa is suspected [7,9,11,12]. One study (of IGF-1) showed a poor clinical correlation [9]. 
Other studies emphasized the need to perform an extensive prostate massage under general 
anesthesia [11,12] or ‘urethral milking’ [4], which would prohibit the use of the test in a 
routine clinical setting. But most importantly, it should be noted that none of the studies 
used standardized, validated methods performed on a routine molecular diagnostic test 
platform.
In our study of prostatic fl uid specimens we have shown that this procedure can be 
performed in a routine clinical setting. Furthermore, we have utilized a test that has been 
validated in diff erent laboratories, performed on a routine molecular diagnostic test platform 
which is suitable and ready for clinical implementation.
Conclusions
To our knowledge, we are the fi rst to examine the diagnostic value of the APTIMA® PCA3 
test using prostatic fl uid samples. Th e results of our exploratory study suggest that the clinical 
utility of this test using prostatic fl uid is comparable to that using urine aft er DRE and that 
both tests can be used to overcome the current problems with PSA testing by improving 
 Molecular PCA3 diagnostics on prostatic fl uid
– 65 –
C
ha
pt
er4
specifi city in PCa diagnosis. A combination of the two specimens may be expected to 
yield higher sensitivity and specifi city. Th is implies that the APTIMA® PCA3 test can be 
performed not only on urine, but also on prostatic fl uid, further expanding the applicability 
of PCA3 gene-based analysis using alternative collection methods.
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Abstract
Background
PCA3-based urine tests have shown to improve the specifi city in prostate cancer (PCa) 
diagnosis, and have thus the potential to reduce the number of unnecessary prostate biopsies 
and to predict repeat biopsy outcomes. In this study, PCA3 was correlated with clinical stage, 
biopsy Gleason score (GS), radical prostatectomy GS, tumor volume, and pathological stage 
to assess its potential as predictor of PCa prognosis. 
Methods
In this study, 351 men admitted for prostate biopsies based on serum prostate-specifi c 
antigen levels > 3 ng/ml, an abnormal digital rectal examination (DRE), and/or a family 
history of PCa were included. Post-DRE urinary sediments from 336 men were tested using 
a transcription mediated amplifi cation-based PCA3 test, and assay results correlated with 
clinical stage and biopsy GS. In a sub-cohort of 70 men that underwent radical prostatectomy, 
the PCA3 values were correlated to their radical prostatectomy GS, tumor volume, and 
pathological stage. 
Results
In this patient cohort we could not fi nd a correlation between PCA3 and clinical stage, 
biopsy GS, radical prostatectomy GS, tumor volume, and pathological stage. 
Conclusions
Th e prognostic value of PCA3 as reported in earlier studies cannot be confi rmed in our 
study. Experimental diff erences (urine sediments vs. whole urine) and cohort may explain 
this. Th e exact place of PCA3 as prognostic test remains subject of investigation. 
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Introduction
Prostate cancer (PCa) is the most frequent malignancy diagnosed in the Western male 
population. In Europe, PCa was diagnosed in 345,900 men and was the cause of death in 
87,400 men in 2006 [1]. Th e high incidence of PCa can be attributed to the increased life 
expectancy of Western males and the implementation of serum prostate-specifi c antigen (PSA) 
testing. Th e introduction of serum PSA in clinical practice has led to the detection of PCa 
at a potentially curable stage. Th ere is objective indication that PSA-based (opportunistic) 
screening has led to overdiagnosis and overtreatment [2]. Many of the detected prostate 
tumors are clinically insignifi cant, i.e. in the absence of screening these tumors would not 
have been diagnosed within the patient’s lifetime. Th is is best illustrated by an increased 
‘incidence mortality ratio’ aft er the introduction of PSA-based screening [3,4]. Currently, it 
is diffi  cult to predict which tumor will show aggressive behavior and which tumor will not. 
Th erefore, overtreatment of localized PCa is a serious clinical issue and there is an urgent 
need for better biomarkers that can distinguish indolent from clinically signifi cant PCa. Th e 
ideal biomarker would be detectable using non-invasive methods, i.e. by means of a blood- or 
urine test. Many candidate biomarkers are currently being identifi ed, however, only few are 
evaluated in multicenter studies using standardized assays. One of the evaluated biomarkers 
is prostate cancer antigen 3 (PCA3). PCA3 is a prostate-specifi c non-coding mRNA which 
is highly over-expressed in more than 95% of primary prostate tumors, with a median 66-
fold up-regulation compared with adjacent non-cancer prostate tissues [5-7]. Th e feasibility 
of PCA3 gene-based molecular tests for the detection of PCa cells in the urine has been 
demonstrated [7-9]. Recently, a quantitative PCA3 urine test with the potential for general 
use in clinical settings was developed [10]. PCA3 gene-based testing on urine samples has 
improved specifi city in the detection of PCa, and thus can lead to a reduction in the number 
of unnecessary prostate biopsies, since it predicts repeat biopsy outcomes more accurately 
[7,11,12].
Limited data are available on the relationship between PCA3 and PCa features. We 
hypothesize that less diff erentiated PCa cells are more invasive and are more likely to 
mobilize and shed into the prostatic ductal system. Th is would result in a higher fraction of 
PCa cells in the fi rst voided urine aft er digital rectal examination (DRE) and thus a higher 
ratio of PCA3 to total prostate mRNA in the specimen. In this study we correlated the 
PCA3 levels in urinary sediments aft er DRE to the biopsy Gleason score (GS) and clinical 
stage in 351 men admitted for prostate biopsies based on serum PSA levels > 3 ng/ml, an 
abnormal DRE, and/or a family history of PCa. Moreover, in patients who underwent a 
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radical prostatectomy, the correlation of PCA3 with prostatectomy GS, tumor volume and 
pathological stage was assessed as well.
Materials and methods
Specimen source
At the urological outpatient clinic of the Radboud University Nijmegen Medical Centre 
fi rst voided urine samples were collected aft er DRE (20 – 30 ml fi rst catch) from 351 men 
scheduled for prostate biopsies based on serum PSA levels > 3 ng/ml, abnormal DRE, and/
or a family history of PCa. Urine specimens were collected between July 2003 and September 
2006 as part of a multicenter study previously described [11]. Men were included with one 
or more previous negative biopsies. A consent form approved by the institutional review 
board was signed by all participants. Th e DRE was performed by applying fi rm pressure from 
the base to apex and from the lateral to the median line for each lobe. 
Aft er urine specimen collection, the urologist performed prostate biopsies according to 
a standard protocol (at least 3 biopsies from the left  peripheral zone, at least 3 biopsies from 
the right peripheral zone, 1 biopsy from the left  transition zone, 1 biopsy from the right 
transition zone, plus additional biopsies from other areas suspicious for PCa when present).
Prostate biopsies and radical prostatectomy specimens were evaluated at the Department 
of Pathology of the Radboud University Nijmegen Medical Centre and in case PCa was 
present the GS was determined. If more than one tumor was reported in a set of biopsies or 
radical prostatectomy specimen, the highest GS was used for evaluation of the prognostic 
value.
Specimen collection and processing
Urinary sediments were obtained and total RNA was extracted as previously described [11]. 
Six μL of extracted RNA was dissolved in 2.6 ml of detergent-based stabilization buff er 
(Sample Transport Medium; STM). Th e PCA3 and PSA mRNA levels were quantifi ed as 
previously described using the PCA3 assay [10]. PSA mRNA expression has been shown 
to be relatively constant in normal prostate cells and PCa cells. Th erefore, the PSA mRNA 
expression is used to normalize for non-cancerous prostate cells; the overall result was defi ned 
as the ratio PCA3 mRNA / PSA mRNA x1,000. 
PCA3 in urinary sediments vs. histopathological characteristics
– 71 –
C
ha
pt
er5
Data analysis
Th e performance of the PCA3 test was evaluated in terms of sensitivity and specifi city by 
comparing PCA3 to biopsy results. Th e diagnostic accuracy of the PCA3 test was compared 
to that of serum PSA. Th e relationship between PCA3 and biopsy GS, clinical stage, prostate 
volume, radical prostatectomy GS, signifi cant versus indolent PCa, and tumor volume was 
also assessed. Indolent PCa was defi ned as organ confi ned cancer with a tumor volume 
< 0.5 cc and the absence of a Gleason grade 4 or 5 disease. Signifi cant PCa was defi ned as all 
cancers not meeting the criteria for indolent PCa. Data were analyzed using the Statistical 
Package for Social Sciences (SPSS, Chicago, IL, USA) version 12.0.1 for Windows. Th e 
nonparametric Mann-Whitney U test or the nonparametric Kruskal-Wallis test was used to 
assess signifi cance levels.
Results
Diagnostic performance of the PCA3 assay
Th e total number of urinary sediments that could be analyzed successfully (i.e. had adequate 
concentrations of PCA3 and PSA mRNA to calculate the PCA3 ratio) was 96% (336 of 
351). In Table I the characteristics of the 336 men in the study are presented. Of the 336 men 
with a PCA3 ratio, 134 men (40%) were found to have PCa upon biopsy. Th ese men were 
signifi cantly older and had a signifi cantly higher serum PSA, higher PCA3 ratio and lower 
prostate volume than the men with negative biopsies. Eighty-one percent of these men had 
a biopsy GS of 6-7.
In Table II the relationship between PCA3 ratio and clinical variables is shown. Th e 
median PCA3 ratio was 18 for the biopsy-negative population and 50 for the biopsy-positive 
population. Th e diff erence between the two populations was highly signifi cant (p < 1.10-11). 
Men with higher prostate volumes had signifi cantly higher serum PSA levels (p < 2.10-5) 
(Table III). In contrast, the PCA3 ratio was independent of prostate volume (p = 0.448) and 
serum PSA (p = 0.097) (Table II).
Th e Area under the curve (AUC) of the Receiver Operating Characteristic (ROC) -curve 
was 0.718 for the PCA3 ratio and 0.649 for serum PSA (data not shown). A PCA3 ratio cut-
off  of 35 provided the optimal balance between sensitivity (61%) and specifi city (74%). In 
comparison, at the same sensitivity the specifi city of serum PSA was 60%. 
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Table II. Relationship between PCA3 Ratio and clinical variables
PCA3 in: N Median Mean P-value
All 336 25  67
Men with:
Negative biopsy 202 18  49 1.4.10-11*
Positive biopsy 134 50  94
Serum PSA:
< 3 ng/ml  26 24  36 0.097**
3-10 ng/ml 219 23  69
> 10 ng/ml  91 32  73
Prostate volume:
< 30 ml  55 25  59 0.448**
30-50 ml 132 27  69
> 50 ml 148 23  69
cT1c  50 38  71 0.088*
cT2  58 56 122
Biopsy GS < 7  81 52  99 0.622*
Biopsy GS ≥ 7  51 38  88
Abbreviations: GS, Gleason score;PCA3, prostate cancer antigen 3;PSA, prostate-specifi c antigen
* Mann-Whitney U test
** Kruskal-Wallis test
Table III. Correlation of serum PSA with prostate volume
Serum PSA in prostate volume: N Median Mean P-value
< 30 ml  55 5.6  6.5 2.3.10-5*
30-50 ml 132 6.3  9.0
> 50 ml 148 7.9 23.7
Abbreviations: PSA, prostate-specifi c antigen
*Kruskal-Wallis test
Th e correlation between PCA3 and biopsy Gleason score
Th e GS could be determined in 132/134 men with PCa-positive biopsies (Table I). In 2 
men the GS could not be determined. In one of these men the amount of PCa in his biopsies 
was too small for GS determination and in the other the prostate tumor in his biopsies was 
classifi ed as a high-grade small-cell neuro-endocrine carcinoma. Men with clinical stage T2 
had a higher median PCA3 ratio than men with clinical stage T1c, although this diff erence 
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was not signifi cant (p = 0.088). No diff erence was observed between the PCA3 ratios of men 
with biopsy GS < 7 and men with biopsy GS ≥ 7 (p = 0.622) (Table II).
Th e correlation between PCA3 and radical prostatectomy Gleason score
Of the 134 men with a positive biopsy result, 70 underwent a radical prostatectomy. Tables IV 
and V list the clinical and pathological characteristics of these patients. Radical prostatectomy 
GS did not equal the biopsy GS in 50% (35/70). Th ere was upgrading in 41% (29 men) 
and downgrading in 9% (6 men) of the cases. Th ere was no correlation between PCA3 and 
tumor volume (p = 0.680). In this cohort, the PCA3 could not discriminate low volume/
low grade PCa (insignifi cant PCa) from signifi cant PCa (p = 0.496). Th e PCA3 ratio could 
not discriminate tumors with GS ≥7 from those with GS < 7 (p = 0.199). Furthermore, the 
PCA3 ratio could not predict extracapsular extension in this patient cohort (p = 0.765).
Table IV. Characteristics of radical prostatectomy population
N Median Mean Range
Age (yr) 70 62 61 49-70
Serum PSA (ng/ml) 70 7.2 10.0 2.1-42.8
Serum PSA < 3 ng/ml  2 3%
Serum PSA 3-10 ng/ml 49 70%
Serum PSA > 10 ng/ml 19 27%
Prostate volume (ml) 70 38 44 18-112
Biopsy GS:
Minimal Cancer  1 (1.4%)
4  2 (2.9%)
5  5 (7.1%)
6 44 (62.9%)
7 (3+4) 14 (20.0%)
7 (4+3)  2 (2.9%)
8  1 (1.4%)
9  1 (1.4%)
Abbreviations: GS, Gleason score; PSA, prostate-specifi c antigen
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Table V. Relationship between PCA3 ratio and pathological variables
PCA3 in: N Median Mean P-value
All 70 42  93
Tumor volume: 56
< 0.5 ml 10 47 105 0.680**
0.804* (< 0.5 ml vs. 0.5 – 2.0 ml)
0.428* (< 0.5 – 2.0 ml vs. > 2.0 ml)0.5 – 2 ml 13 33  68
> 2 ml 33 52 116
Insignifi cant or signifi cant PCa
Insignifi cant PCa  5 42  44 0.496*
Signifi cant PCa 54 45 109
Prostatectomy Gleason score:
4  1 42
5  7 20 241
6 21 32  54
7 30 54 100
8  4 99  96
9  5 42  44
< 7 29 32  99 0.199*
≥ 7 39 52  92
Pathological stage:
pT2 40 53 108 0.765*
pT3 28 38  77
Biochemical recurrence:
No 46 52  97 0.449*
Yes 21 37  92
Abbreviations: GS, Gleason score; PCa, prostate cancer; PCA3, prostate cancer antigen 3; PSA, prostate-specifi c antigen
* Mann-Whitney U test
** Kruskal-Wallis test
Discussion
In this study we investigated the correlation between the PCA3 ratio and histopathological 
features known to be associated with PCa aggressiveness. Independent predictors of 
pathological stage and prognosis are clinical stage, serum PSA and Gleason grade. Th e 
Gleason scoring system is regarded as the most powerful prognostic factor in PCa [13]. Men 
who have organ-confi ned disease and a GS 7 tumor have signifi cant worse outcome aft er 
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radical prostatectomy and radiotherapy than men with a GS ≤ 6 tumor [14]. Diff erentiation 
between GS ≤ 6 and ≥ 7 is important for treatment decision. However, the 50% grade 
discrepancy (biopsy versus radical prostatectomy) seen in this study indicates the need for 
better predictors of pathological stage and cancer aggressiveness. Several studies have shown 
that PCA3 was superior to serum PSA testing for predicting biopsy outcome [12,15]. Two 
reports have shown a correlation between urinary PCA3 and prostatectomy GS, tumor size, 
PCa signifi cance or extracapsular extension [16,17]. 
In this study, we were unable to confi rm a correlation between PCA3 and pathologic 
features. We used post-DRE urinary sediments, while previous studies that showed a positive 
correlation utilized whole urine. It is possible that post-DRE whole urine would have yielded 
diff erent results for our cohort.
Th e inconsistency of results might also be explained by diff erences among subject groups. 
In a recent Dutch multicenter study we observed that the study population is important for 
performance characteristics [11]. Th e current study is based on men admitted for prostate 
biopsies because of elevated serum PSA values (> 3 ng/ml), an abnormal DRE, and/or a 
family history of PCa. Some of these patients had a history of one or more negative biopsies. 
Th e mean serum PSA value in our cohort is higher (15.6 ng/ml) when compared to the 
serum PSA values in recent studies (~6 ng/ml) [12,15]. In several studies it was shown that 
PCA3 can improve specifi city in the diagnosis of PCa when compared to serum PSA [12,15]. 
Th e PCA3 assay performance was shown to be similar at all serum PSA levels [15]. In our 
study cohort, the PCA3 ratio was also signifi cantly higher in the biopsy positive population 
compared to the biopsy negative population (p < 1.10-11). Th e PCA3 ratio was independent 
of prostate volume, confi rming previous data [15]. A PCA3 cut-off  value of 35 provided an 
optimal balance between sensitivity (61%) and specifi city (74%). Th e area under the curve 
of 0.718 for PCA3 was higher than that for serum PSA (0.649, data not shown). It is not 
surprising that serum PSA performs better in this study cohort compared to its performance 
in a screen-based population. It is well known that the cancer detection rate is much higher 
in men with serum PSA values > 10 ng/ml (> 46%) compared to men with serum PSA values 
between 3 and 10 ng/ml (~30%) [18,19]. However, even in this patient cohort, PCA3 had a 
higher specifi city compared to that of serum PSA in the diagnosis of PCa.
Th e previous reports on the relationship between PCA3 and PCa tumor features were 
performed in the US. Recently, it was shown that despite a stage migration to lower stages 
in the US, the fraction of GS 7 cancer increased, whereas in Europe the patients with GS 6 
increased [20]. In an analysis of 11,350 men treated with radical prostatectomy it was shown 
that patients from the US were younger and had lower serum PSA values at presentation 
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[20]. In our study cohort the median age of men diagnosed with PCa was 65 years, and 62 
years for men scheduled for prostatectomy. In the US studies, the median age of the patient 
cohort scheduled for radical prostatectomy is ~59 years [16,17]. Th e observed diff erences 
are consistent with opportunistic screening and PCa detection in the US versus low to no 
penetration of screening in the Netherlands.
In our cohort 62% of men with PCa had a biopsy GS ≤ 6, whereas in previous studies on 
the predictive value of PCA3 the number of men with biopsy GS ≤ 6 was lower (41 – 55%) 
[16,17]. Th ese data are in concordance with recent fi ndings in which patients in the US had 
a higher rate of palpable cancer and a higher rate of biopsy GS 7 – 10 than their European 
counterparts [20]. Furthermore, we observed a disappearance of biopsy GS ≤ 5 in the US 
study cohort [16,17]. It has been shown that the grade interpretation of pathologists in the 
US has shift ed towards higher biopsy grades compared to 10 years ago [21]. Th ere is an 
increasing incidence in detection of moderately diff erentiated PCa at biopsy and a decreasing 
incidence in well and poorly diff erentiated cancer at biopsy [22]. Th e less universal adherence 
of the Europeans to the recommendations for grading of biopsy specimens may account for 
the fact why no decrease in biopsy GS ≤ 5 was observed in the European cohort. However, 
these fi ndings may have clinical implications, since prediction tools developed in the US may 
perform diff erently in European patients due to the grade migration described above [20].
Our results are consistent with the fi ndings by Nakanishi et al. that there is no correlation 
between PCA3 ratio and clinical stage. In the biopsy population of our patient cohort no 
signifi cant diff erence was found between PCA3 ratio and biopsy GS < 7 versus ≥ 7 (p = 0.622). 
Although previous studies did not fi nd a signifi cant correlation between PCA3 ratio and 
biopsy GS either, there was an important diff erence between the data. In our patient cohort, 
biopsy GS < 7 had a higher median PCA3 ratio (52) compared to biopsy GS ≥ 7 (39). In 
the studies by Deras et al. and Nakanishi et al., biopsy GS 6 had a lower median PCA3 score 
compared to biopsy GS ≥ 7 (38 vs. 41 and 48 vs. 55 respectively) [15,16]. Again, it should be 
noted that we determined the PCA3 ratios in urinary sediments. Th erefore, the PCA3 ratios 
cannot be compared at the level of absolute values with those determined in whole urine.
A hint in the direction that patient cohort may account for diff erences came from a 
recent European study [23]. In the multicenter study by Haese et al., only men were included 
who had one or two previous negative biopsies and who were scheduled for repeat biopsy. 
In their patient cohort, PCA3 did correlate with biopsy GS and clinical stage, and was 
signifi cantly higher in signifi cant PCa compared to indolent PCa. Th erefore, in men with 
one or two previous negative biopsies scheduled for repeat prostate biopsy, PCA3 may aid 
in the decision which patients need a repeat biopsy and may be indicative of the signifi cance 
of PCa.
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We also analyzed the corresponding radical prostatectomy specimen, in which the GS can 
be determined more accurately. In our patient cohort, 52% of men with PCa were scheduled 
for radical prostatectomy. Seventy-four percent of these men had biopsy GS < 7 and 26% had 
biopsy GS ≥ 7. In the study by Nakanishi et al., 41% had a biopsy GS < 7 and 59% had biopsy 
GS ≥ 7. It is unclear whether this refl ects systematic diff erences in Gleason grading or that 
US surgeons are more willing to operate on higher risk patients [20].
In our study population, the prostatectomy GS did not match the biopsy GS in 50% 
of the cases. Upgrading occurred in 41% of the men and downgrading in 9% of the men. 
Twenty-nine men had prostatectomy GS < 7, whereas 39 men had prostatectomy GS 
≥ 7. Th e median PCA3 ratio for prostatectomy GS < 7 was lower than the median PCA3 
ratio for prostatectomy GS ≥ 7, although this diff erence was not signifi cant (32 versus 52, 
p = 0.199).
In the study by Nakanishi et al., biopsy GS did not equal the prostatectomy GS in 41% of 
the cases (upgrading in 31 men and downgrading in 8 men). Only 15 men had prostatectomy 
GS 6, whereas 81 men had prostatectomy GS ≥ 7. Th e PCA3 score was signifi cantly higher 
in patients with prostatectomy GS ≥ 7 compared to those with prostatectomy GS 6 tumors 
(p = 0.005) [16].
In the radical prostatectomy population of the study by Whitman et al., 42 men had 
GS 6 and 30 GS ≥ 7 PCa. Th e median PCA3 score for prostatectomy GS 6 was less than 
the median PCA3 score for GS ≥ 7 PCa, but the diff erence was not signifi cant (21.3 versus 
30.8, p = 0.22). Furthermore, the median PCA3 score was 25 and this was relatively lower 
compared to other studies. Whitman et al. suggested that patient population could account 
for the observed diff erences. Th eir population consisted of a relative high percentage (25%) 
of African American men. African American men represent a group at a particularly high 
risk for developing PCa. Signifi cant diff erences in the frequency of risk alleles in these men 
have been identifi ed and might, in part, explain an increased susceptibility to PCa.
In our patient cohort, the number of patients with extracapsular extension was higher 
(40%) compared to the study by Nakanishi et al. (18%) and Whitman et al. (29%). Th is 
is most likely due to the inclusion of patients with a higher pre-operative serum PSA. Th is 
results in a higher rate of pT3 stage at prostatectomy compared with other studies and a 
high incidence of biochemical recurrence (30%) aft er radical prostatectomy [24]. We could 
not fi nd a correlation between PCA3 score and extracapsular extension in this cohort. 
Whitman et al. suggested that the increased frequency of pT3 disease observed in their 
study cohort could have been the result of increased detection from analyzing the prostate 
in whole mounted sections with smaller intervals [17]. In contrast to our study and the study 
PCA3 in urinary sediments vs. histopathological characteristics
– 79 –
C
ha
pt
er5
by Nakanishi et al., men with pT3 disease had a higher median PCA3 score compared to 
patients without extracapsular extension (48.7 versus 18.7, p = 0.02) [17]. 
When combining the results from all the studies on the predictive value of PCA3 for 
adverse histopathological features, yet unexplained discrepancies are revealed. Th ree variables 
may explain the diff erences. First, there are systematic diff erences in Gleason grading, which 
is best illustrated by the paradoxical high fraction of GS 7 cancers in US cohorts. Second, 
it should be stressed that due to the original study design urinary sediments were analyzed, 
which may have yielded diff erent results than whole urine utilized in other studies [11], and 
third, our patient cohort had relatively few men with favorable prognostic outcome. Further 
studies are needed to assess the exact position of PCA3 testing in the clinical management 
of PCa.
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Abstract
Background
Due to the drawbacks of serum prostate-specifi c antigen, there is an ongoing search for new 
diagnostic and prognostic prostate cancer (PCa) markers. PCA3 has proven to be of value 
in the diagnosis of PCa. However, so far few attempts have been made to investigate the 
prognostic value of PCA3. Our objective was to further investigate the prognostic value of 
PCA3.
Methods
In this study we correlated the PCA3 score in urinary sediments aft er digital rectal examination 
in 62 men with the classical prognostic parameters assessed in radical prostatectomy specimens 
(i.e. Gleason score, pathological tumor stage and total tumor volume) and moreover, with 
the expression of three immunohistochemical markers for PCa biological aggressiveness (i.e. 
E-cadherin, alpha-catenin and EZH2). Th e results from this study serve as a refl ection on 
and a valuable adjunct to recently published results.
Results
We did not fi nd a signifi cant correlation of the PCA3 score with the classical prognostic 
parameters assessed in radical prostatectomy specimens or the expression of the 
immunohistochemical markers for PCa biological aggressiveness. However, we did observe a 
trend for a higher PCA3 score in signifi cant PCa vs. insignifi cant PCa, aberrant E-cadherin 
staining vs. normal E-cadherin staining and increased EZH2 staining vs. normal EZH2 
staining.
Conclusions
In this study we could not prove the prognostic value of PCA3. Further research with large 
numbers of men and adequate follow-up is needed to provide a defi nitive answer to the 
question if PCA3 is not only a diagnostic but also a prognostic PCa marker.
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Introduction
Th e role of serum prostate-specifi c antigen (PSA) as the standard diagnostic and prognostic 
prostate cancer (PCa) marker is being questioned [1,2]. Because PSA is not cancer-specifi c 
it lacks specifi city as a diagnostic marker, resulting in a high negative biopsy rate. Moreover, 
its use is associated with certain drawbacks, e.g. the diagnosis of clinically irrelevant tumors 
(i.e. overdiagnosis) and potential overtreatment [1]. Th erefore, there is an ongoing search 
for new PCa markers that can improve the specifi city in PCa diagnosis and can diff erentiate 
between clinically irrelevant and clinically signifi cant disease.
Prostate cancer gene 3 (PCA3) is a prostate-specifi c, non-coding mRNA that is highly 
overexpressed in PCa tissue compared with benign prostate tissue [3,4]. A dual time resolved 
fl uorescence-based RT-PCR assay was developed to investigate the use of PCA3 gene 
expression to identify PCa cells in urinary sediments aft er digital rectal examination (DRE)
[5]. In a pilot study the PCA3 urine test showed potential to improve the specifi city in PCa 
diagnosis [5], and its diagnostic performance was validated in a Dutch multicenter study 
[6]. Others have confi rmed the value of PCA3 as a diagnostic PCa marker using whole urine 
samples and a somewhat diff erent test method (developed by Gen-Probe Inc., San Diego, 
CA, the United States of America) [7-9].
However, so far few attempts have been made to investigate the prognostic value of 
PCA3.
Several reports have compared PCA3 mRNA expression in tissue between radical 
prostatectomy (RP) specimens with diff erent Gleason scores and did not fi nd a signifi cant 
positive correlation [4,10,11], or have suggested a negative one [12]. Bostwick et al. concluded 
that the PCA3 urine test did not preferentially identify aggressive PCa’s [13]. Just recently, 
Deras et al. correlated the PCA3 score in urinary sediments aft er DRE with the Gleason 
score (GS) in subsequent prostate biopsies in 196 men with PCa. Th e PCA3 scores for GS 
6 vs. ≥ 7 were not signifi cantly diff erent [14]. Nakanishi et al. assessed the association of the 
urinary PCA3 score with prostatectomy tumor volume and other clinical and pathologic 
features, using whole urine samples and the PCA3 test developed by Gen-Probe [15]. Th ey 
concluded that the PCA3 score appears to stratify men based on tumor volume and may 
have clinical applicability in selecting men who have low-volume/low-grade cancer.
We hypothesized that since aggressive PCa cells are more invasive, they would be more 
likely to mobilize and shed into the prostate ductal system. Th is would result in a higher 
percentage of PCa cells to be collected with the fi rst voided urine aft er DRE and thus a 
higher PCA3 score. In the same way a larger tumor would shed more PCa cells, resulting in 
a higher PCA3 score.
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In addition to the classical prognostic parameters assessed in RP specimens, i.e. GS, tumor 
stage and total tumor volume, we analyzed the expression of three immunohistochemical 
markers for PCa biological aggressiveness: the cell-cell adhesion molecules E-cadherin 
[16,17] and α-catenin [17,18] and the human homolog of the Drosophila enhancer of zeste 
gene (EZH2) [19,20].
In this study, we correlated the PCA3 score in urinary sediments aft er DRE with the 
classical prognostic parameters assessed in RP specimens and moreover with the expression 
of three immunohistochemical markers for PCa biological aggressiveness. Th e results from 
this study serve as a refl ection on the results of Nakanishi et al. and as a valuable adjunct to 
recent literature, further investigating the prognostic value of PCA3 gene-based analysis.
Materials and Methods
Study design
In our university hospital urological outpatient clinic, as part of a multicenter study described 
earlier, the fi rst voided urine aft er DRE was collected from men who were to undergo 
ultrasound-guided, transrectal, prostate biopsies as a result of local management [6].
Th e institutional review board had approved the study. Beforehand, all men had received 
study information and they had signed their written informed consent. All samples and data 
were collected prospectively.
Urinary sediments were obtained and total RNA was extracted as described previously 
[6]. Eight microliters of extracted RNA was dissolved in 2.6 ml of detergent-based 
stabilization buff er, which lyses the cells and stabilizes the RNA [7]. Th e PCA3 and PSA 
mRNA transcripts were amplifi ed and quantifi ed with the PCA3 test developed by Gen-
Probe according to the protocol described earlier by Groskopf et al. [7]. Th e ratio PCA3 
/PSA mRNA was then calculated by dividing the number of PCA3 mRNA copies by the 
number of PSA mRNA copies obtained in a given sample. Th e PCA3 score was defi ned as 
the ratio PCA3/PSA mRNA x1,000.
Sixty two men that were diagnosed with PCa upon biopsy were subsequently treated by 
laparoscopic or open retropubic RP. None of them received neo-adjuvant treatment in the 
form of gosereline, bicalutamide or leuproreline.
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RP specimen processing
Following surgical resection, all RP specimens were handled according to a standard protocol 
[21]. Our institutional uropathologist (CAHvdK) reviewed all RP tissue specimens. All 
tumors were graded according to the Gleason grading system [22]. When multiple tumors 
were found in one specimen and the diff erent tumors had diff erent GSs, the (tumor with the) 
highest GS was chosen for analysis.
Th e 2002 TNM Classifi cation of malignant tumors was used for pathological tumor 
staging [23] and capsule penetration was defi ned as the presence of malignant cells in the 
periprostatic fatty tissue.
Tumor volume was calculated as described earlier [21], but no tissue shrinkage correction 
factor was used. Total tumor volume was calculated by adding up the volumes of the diff erent 
tumors in one specimen.
Insignifi cant cancer was defi ned as organ-confi ned cancer, with a dominant tumor 
≤ 0.5 ml in volume, with no Gleason pattern four or fi ve (i.e. GS ≤ 6) [24].
Immunohistochemical staining
For immunohistochemical staining several 4-micrometer paraffi  n tissue sections were taken 
from the prostate tumor with the highest GS and mounted on slides. Aft er deparaffi  nization, 
slides were washed in phosphate buff ered saline (PBS). Endogenous peroxidase was inhibited 
by incubation for 30 minutes in 0.6% hydrogen peroxide and 40% methanol in PBS. Slides 
were washed three times in tap water. Antigens were retrieved by using citrate (0.01 M, pH 
6.0) during 10 minutes in microwave. Aft er cooling, slides were washed three times in tap 
water and once in PBS (only for E-cadherin and α-catenin this was PBS containing 1 mM 
CaCl2 en 1 mM MgCl2). Only for EZH2 the slides were then incubated for 5 minutes in 
PBS containing 0.5% Triton X-100, and subsequently washed in PBS for three times fi ve 
minutes. Th e slides were then incubated for 10 minutes in 0.1 M glycine (diluted in PBS), 
rinsed in PBS only for three times fi ve minutes and then incubated for one hour with primary 
antibody in PBS 1% BSA. Th e antibodies used were: the HECD-1 mouse monoclonal 
antibody for E-cadherin (1:200, TaKaRa Bio, Shiga, Japan), mouse monoclonal antibody for 
α-catenin (1:50, BD Biosciences, Breda, Th e Netherlands) and mouse monoclonal antibody 
for EZH2 (1:50, BD Biosciences, Breda, Th e Netherlands). Slides were washed in PBS for 
three times fi ve minutes, were incubated for 30 minutes with the secondary antibody Poly-
HRP-GAM/R/R IgG (Immunologic, Duiven, Th e Netherlands) and were washed in PBS 
for three times fi ve minutes. Immunostaining was performed with PowerVision DAB (cat no. 
BS03-25, Immunologic, Duiven, Th e Netherlands). Slides were rinsed in water and sections 
were counterstained with hematoxylin and mounted in permount aft er dehydration.
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Th e staining patterns of both E-cadherin and α-catenin were scored as either normal 
(membrane staining) or aberrant (negative or heterogeneous staining, i.e. mixed populations 
of positive and negative cells, Figure 1A and B) as previously described [16-18]. EZH2 
staining was scored as either normal (no or only a very sporadic EZH2 positive cell(s) 
present) or increased (one or a few EZH2 positive cell(s) present, Figure 1C and D) roughly 
corresponding with the dichotomized maximal staining percentages of 0-1% vs. ≥ 1% 
previously described [19]. Consensus was reached among three observers (MPMQvG, DH, 
CFJJ) on the evaluation of each staining without prior knowledge of the tumor grade or 
stage, or PCA3 score.
Figure 1. Prostate cancer tissue with normal (A) and aberrant (B) E-cadherin or alpha-catenin staining 
pattern and normal (C) or increased (D) EZH2 staining pattern. Original magnifi cation 400x.
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Statistical analysis
Data were analyzed using the Statistical Package for the Social Sciences (SPSS, Chicago, 
IL, USA) version 15.0.1 for Microsoft  Windows. We used the two-tailed Mann-Whitney 
U test to test for diff erences in PCA3 score between men with diff erent GSs, with 
insignifi cant and signifi cant PCa, with diff erent pathological tumor stages and with diff erent 
immunohistochemical staining patterns. To test for a correlation between PCA3 score 
and total tumor volume, we used the two-tailed Spearman’s rho test. A p value < 0.05 was 
considered signifi cant.
Results
Th e clinical, prostate biopsy and RP features of the 62 men are presented in Table I.
RP GS
Th e median PCA3 score for men with RP GS ≤ 6 PCa was 39 (range 0 – 1355), the median 
score for men with RP GS ≥ 7 PCa was 42 (range 0 – 585, Figure 2). Th e diff erence was not 
signifi cant (p = 0.90).
Total tumor volume
PCA3 score was plotted against total tumor volume in a scatter plot (Figure 2). Spearman’s 
rho test revealed no signifi cant correlation between total tumor volume and PCA3 score 
(p = 0.96).
Insignifi cant and signifi cant PCa
For men with insignifi cant PCa the median PCA3 score was 25 (range 0 – 204) and for 
men with signifi cant PCa 44 (range 0 – 1355, Figure 2). Th e diff erence was not signifi cant 
(p = 0.38).
Pathological tumor stage
Th e median PCA3 score for men with pathological tumor stage 2 (pT2) PCa was 52 (range 
0 – 1355), the median score for men with pT3 PCa was 37 (range 0 – 363, Figure 2). Th e 
diff erence was not signifi cant (p = 0.59).
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Table I. Clinical, prostate biopsy and radical prostatectomy features
Mean ± SD No. of men %
Total study population 62 100
Clinical features
Age (years) 62 ± 4.9 62 100
Serum PSA value (ng/ml) 9.88 ± 8.61 62 100
PCA3 score* 101 ± 196 62 100
Total prostate volume** (ml) 40.2 ± 17.4 59  95
Clinical stage
cT1c 29  47
cT2 31  50
cT3  2   3
Prostate biopsy features
Biopsy Gleason score
4  1   1.6
5  6  10
6 37  60
7 16  26
9  1   1.6
10  1   1.6
Radical prostatectomy features
Surgical method
Laparoscopic 32  52
Open retropubic 30  48
Gleason score
5  5   8
6 21  34
7 28  45
8  2   3
9  6  10
Biopsy Gleason score vs. radical prostatectomy Gleason score
Identical 32  52
Upgrading 25  40
Downgrading  5   8
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(Continued) Mean ± SD No. of men %
Pathological stage
pT2 35  56
pT3 27  44
Volume largest tumor (ml) 3.3 ± 3.6 62 100
Total tumor volume (ml) 3.6 ± 3.6 62 100
Insignifi cant or signifi cant cancer
Insignifi cant cancer  8  13
Signifi cant cancer 54  87
* Th e median PCA3 score was 42 (range 0 - 1355)
** Measured by transrectal ultrasonography at the time of biopsy
E-cadherin
Th e E-cadherin staining pattern in PCa tissue was normal in 37 men (60%) and aberrant 
in 21 (34%). In four men (6%) the E-cadherin staining pattern could not be scored, due to 
staining problems.
For men with a normal E-cadherin staining pattern the median PCA3 score was 32 
(range 0 – 1355) and for men with an aberrant staining pattern 52 (range 0 – 470, Figure 3). 
Th e diff erence was not signifi cant (p = 0.34).
Alpha-catenin
Th e α-catenin staining pattern in PCa tissue was normal in 50 men (81%) and aberrant in 9 
(15%). In three men (5%) the α-catenin staining pattern could not be scored, due to staining 
problems.
For men with a normal α-catenin staining pattern the median PCA3 score was 41 (range 
0 – 1355) and for men with an aberrant α-catenin staining pattern 42 (range 31 – 156, 
Figure 3). Th e diff erence was not signifi cant (p = 0.53).
EZH2
EZH2 staining in PCa tissue was normal in 39 men (63%) and increased in 20 (32%). In 
three men (5%) EZH2 staining could not be scored, due to staining problems.
For men with normal EZH2 staining the median PCA3 score was 37 (range 0 – 1355) and 
for men with increased EZH2 staining 53 (range 0 – 470, Figure 3). Th e diff erence was not 
signifi cant (p = 0.56).
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Figure 2. Th e correlation of the PCA3 score with the classical prognostic parameters assessed in 
radical prostatectomy specimens. Th ree boxplots (also known as a ‘box-and-whisker diagrams’) and a 
scatterplot:
boxplot showing the distribution of PCA3 scores for men with Gleason score ≤ 6 and men with  –
Gleason score ≥ 7 prostate cancer (upper left )
scatterplot with the PCA3 score plotted on the vertical axis and the total tumor volume plotted on  –
the horizontal axis (upper right)
boxplot showing the distribution of PCA3 scores for men with insignifi cant and men with  –
signifi cant prostate cancer (lower left )
boxplot showing the distribution of PCA3 scores for men with pathological tumor stage 2 (pT2)  –
and men with pathological tumor stage 3 (pT3) prostate cancer (lower right)
In the boxplots, the median value (thick black horizontal line), outliers (open circles) and extremes 
(stars) are shown. Th e box length is the interquartile range and the ‘whiskers’ extend to 1.5 times this 
distance.
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Figure 3. Th e correlation of the PCA3 score with 
the expression of three immunohistochemical 
markers for prostate cancer biological 
aggressiveness. Th ree boxplots showing the 
distribution of PCA3 scores for:
men with a normal and men with an  –
aberrant E-cadherin staining pattern in 
prostate cancer tissue (top)
men with a normal and men with an  –
aberrant alpha-catenin staining pattern in 
prostate cancer tissue (middle)
men with normal and men with increased  –
EZH2 staining in prostate cancer tissue 
(bottom)
In the boxplots, the median value (thick black 
horizontal line), outliers (open circles) and 
extremes (stars) are shown. Th e box length 
is the interquartile range and the ‘whiskers’ 
extend to 1.5 times this distance.
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Discussion
We correlated the PCA3 score in urinary sediments aft er DRE in 62 men with the 
classical prognostic parameters assessed in RP specimens and the expression of three 
immunohistochemical markers for PCa biological aggressiveness. We did not fi nd a 
signifi cant correlation of the PCA3 score with the classical prognostic parameters assessed 
in RP specimens or the expression of the immunohistochemical markers for PCa biological 
aggressiveness. However, we did observe a trend (that did not reach signifi cance) for a higher 
PCA3 score in signifi cant PCa vs. insignifi cant PCa, aberrant E-cadherin staining vs. normal 
E-cadherin staining and increased EZH2 staining vs. normal EZH2 staining.
Nakanishi et al. recently reported that although in biopsy specimens there was no 
signifi cant diff erence between the PCA3 score in men with GS ≤ 6 and ≥ 7 PCa, they found 
a signifi cant association between the PCA3 score and RP GS in a group of 96 men [15]. 
A possible explanation could be the problem of upgrading and downgrading from biopsy 
specimens to RP specimens (respectively 40% and 8% in our study). Naturally, relatively 
small sample size could be an explanation for the diff erence between the results reported 
by Nakanishi et al. and our own. Another explanation could be the considerable patient 
selection for RP. Men with lower GSs are considered candidates for other treatment options, 
e.g. active surveillance or brachytherapy, and could therefore be underrepresented in the study 
population. Th e same is true for men with high GSs. However, the treatment choice made 
could diff er from one clinic to another. An additional item that could be of infl uence, is the 
specifi c sample type used. As we have done earlier [25], in this study we used the sediments 
of urine samples whereas Nakanishi et al. used whole urine samples. A possible advantage 
of using the sediment of a urine sample may be that the size of the sample is increased by 
concentrating all the cells and cell fragments in the sediment, instead of only analyzing part 
of the total sample [25]. Moreover, the Gleason grading system, like all histological grading 
methods, possesses an inherent degree of subjectivity and therefore intra- and interobserver 
variability does exist [26].
In addition, contrary to Nakanishi et al. we did not fi nd a signifi cant association of the 
PCA3 score with total tumor volume [15]. Again, the relatively small sample size and the 
specifi c sample type used could be explanations for the diff erence.
In accordance with Nakanishi et al. we found a trend for a higher PCA3 score in signifi cant 
PCa vs. insignifi cant PCa, although in our study this diff erence was not signifi cant [15]. In 
our study, there were only eight men with insignifi cant PCa and 54 men with signifi cant PCa, 
vs. 11 and 85 men respectively in the article by Nakanishi et al. Perhaps this is an explanation 
for the diff erence in signifi cance.
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Pathological tumor stage is also believed to be an important predictor of prognosis. In 
our study, in accordance with Nakanishi et al., men with a pT3 tumor did not have a higher 
PCA3 score than men with a pT2 tumor [15]. It seems that the shedding of PCa cells in the 
prostate ductal system and the extension of a PCa tumor through the prostatic capsule or 
into the seminal vesicles are two separate biological processes. Again, another explanation 
could be the relatively small sample size in both studies.
For the fi rst time the PCA3 score in urinary sediments aft er DRE was correlated to 
the expression of immunohistochemical markers for PCa biological aggressiveness in RP 
specimens.
E-cadherin is a cell-cell adhesion molecule. Loss of normal E-cadherin expression in 
PCa leads to decreased cell-cell adhesion, promoting tumor invasiveness and is therefore 
associated with a poorer prognosis [16,17]. In our study, the (non signifi cant) trend found 
for a higher PCA3 score in men with PCa with aberrant E-cadherin staining vs. normal 
E-cadherin staining could be a refl ection of the increased shedding of PCa cells in the 
prostate ductal system by the loss of cell-cell adhesion. Th e lack of a signifi cant association 
could be explained by the relatively small sample size.
Alpha-catenin links the cell-cell adhesion molecule E-cadherin to the cytoskeleton. 
Th erefore, the loss of normal α-catenin expression in PCa could be one of the mechanisms 
responsible for the loss of E-cadherin-mediated cell-cell adhesion and thus be associated 
with a poorer prognosis as well [17,18]. In our study, we found no diff erence in PCA3 score 
between men with PCa with aberrant α-catenin staining vs. normal α-catenin staining. Th is 
diff erence between the association E-cadherin staining – PCA3 score and the association 
α-catenin staining – PCA3 score is intriguing, but perhaps the most likely explanation is 
simply the relatively small sample size (i.e. the E-cadherin staining pattern was aberrant in 21 
men and the α-catenin staining pattern in 9).
EZH2 is a polycomb-group protein and its vital role is maintenance of cell identity 
and regulation of the cell cycle. EZH2 overexpression in PCa is associated with a poorer 
prognosis [19,20]. In our study, we did observe a trend (that did not reach signifi cance) 
for a higher PCA3 score in men with PCa with increased EZH2 staining vs. normal EZH2 
staining. Th is could be an indication for PCA3 as a prognostic parameter. Again, the lack of 
a signifi cant association could be explained by the relatively small sample size.
It was not our goal to confi rm the value of E-cadherin, α-catenin and EZH2 as 
immunohistochemical markers for PCa biological aggressiveness. Th e expression of these 
three markers was not signifi cantly associated with RP GS or pT stage in our study (data not 
shown), but this could easily be explained by the relatively small sample size.
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Conclusions
In our study, we did not fi nd a signifi cant correlation of the PCA3 score with RP GS or 
total tumor volume. Th erefore, we could not prove our hypothesis. Th e most important 
limitations of our study would be the relatively small sample size and the homogeneity of the 
population that was selected for RP. As a consequence, the defi nitive answer to the question 
if PCA3 is not only a diagnostic but also a prognostic PCa marker, can only come from the 
implementation of the PCA3 urine test in larger studies with adequate follow-up.
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Abstract
Background
Dutasteride is commonly used in patients that are also at risk for prostate cancer (PCa). 
Th erefore, the infl uence of dutasteride on PCa markers has to be studied. To date, only 
the eff ect of dutasteride on serum prostate-specifi c antigen (PSA) has been studied. Th is 
was the fi rst study to investigate the eff ect of dutasteride on the new PCa marker PCA3, 
longitudinally and in a dose dependent manner.
Methods
From April 25th 2005 to October 31st 2006, 16 subjects with benign prostatic hyperplasia 
(BPH) and nine subjects with clinically localized PCa were enrolled at the urological 
outpatient clinics of one university hospital and one community hospital. Eight subjects with 
BPH and fi ve with PCa received 0.5 mg dutasteride once daily for three months, eight with 
BPH and four with PCa received 3.5 mg. No subjects were withdrawn because of adverse 
eff ects.
Results
In all four groups both 0.5 mg and 3.5 mg dutasteride had a variable eff ect on the PCA3 score. 
In contrast, its other eff ects were consistent as it rapidly reduced serum DHT by ≥ 90%, over 
time increased serum T by 20 – 30%, over time halved serum PSA and decreased prostate 
volume by 10 – 16%.
Conclusions
In this exploratory/pilot study the eff ect of dutasteride on the PCA3 score was variable. Th is 
should be should be taken into account while using PCA3 in diagnostics. As this study was 
exploratory, the infl uence of androgen-deprivation therapy on the PCA3 score should be 
analyzed further.
Th e eff ect of dutasteride on PCA3
– 99 –
C
ha
pt
er 7
Introduction
Prostate cancer (PCa) is the most common cancer in men. Th e estimated number of new cases 
in Europe in the year 2006 was 345,900, accounting for about 20% of all newly diagnosed 
cancers in European men. Th e estimated number of PCa deaths was 87,400, accounting for 
about 9% of all cancer deaths in European men [1].
Dutasteride is a dual 5α-reductase inhibitor (5ARI) used in the treatment of lower 
urinary tract symptoms associated with benign prostatic hyperplasia (BPH), either as 
monotherapy [2], or in combination with an α-blocker [3]. Dutasteride exerts its eff ect on 
prostate tissue by binding both the type 1 and type 2 isoenzymes of 5α-reductase (5AR) 
to inhibit the conversion of the androgen testosterone (T) to the more potent androgen 
dihydrotestosterone (DHT). In diff erent daily doses, dutasteride has shown to provide near-
maximal suppression of serum and more importantly intraprostatic DHT levels in both men 
with BPH and men with PCa [4-6].
Pooled data from phase III studies in BPH showed that dutasteride signifi cantly reduced 
PCa, reported as an adverse event, in men with BPH [7]. Th is led up to the REduction 
by DUtasteride of prostate Cancer Events (REDUCE) trial that tests the hypothesis that 
treatment with dutasteride decreases the incidence and progression of PCa by the suppression 
of prostatic DHT [8]. At the same time, the REduction by Dutasteride of clinical progression 
Events in Expectant Management (REDEEM) trial evaluates the potential for dutasteride 
to delay disease progression in men with biopsy-proven, low-risk, localized PCa that are 
candidates for expectant management [9].
Prostate cancer gene 3 (PCA3) is a new PCa marker. It is a prostate-specifi c, non-coding 
mRNA that is highly overexpressed in PCa tissue compared with benign prostate tissue 
[10,11]. Its value as a diagnostic marker by means of the PCA3 score identifying PCa cells in 
urine or urinary sediments aft er digital rectal examination (DRE) has been shown in several 
large multicenter studies [12-15]. In vitro data has shown that, similar to the expression of 
prostate-specifi c antigen (PSA), the expression of PCA3 is androgen sensitive [16,17].
Pending the results of the two abovementioned large trials [8,9], there may be an increasing 
role for dutasteride in PCa risk reduction and even the early treatment of PCa in the near 
future. Follow up with PCa markers during dutasteride treatment will be crucial, but to date 
only the eff ect of dutasteride on serum PSA has been studied [18]. To our knowledge, there 
has been no report of the eff ect of dutasteride on PCA3. Filling this void, this exploratory 
randomized, open-label, parallel-group pilot study is the fi rst study to investigate the eff ect 
of dutasteride on the PCA3 score, longitudinally and in a dose dependent manner, in both 
men with BPH and men with clinically localized PCa.
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Materials and Methods
Study design and population
Th is was a randomized, open-label, parallel-group pilot study, to assess the eff ect on the 
PCA3 score, longitudinally and in a dose dependent manner, of 0.5 mg or 3.5 mg dutasteride 
administered orally once daily, for three months in men with BPH and men with biopsy-
proven, clinically localized PCa.
In the urological outpatient clinics of one university and one community hospital, the 
charts of both men with BPH and men with clinically localized PCa who had underwent a 
prostate biopsy within the last 6 months were reviewed for inclusion in this study (MPMQvG 
and HV). Possibly eligible subjects were contacted and invited for a fi rst screening visit. On 
the second visit, i.e. the baseline visit, all eligible subjects were enrolled and randomized by a 
random draw of an unmarked, sealed envelope containing the dose (MPMQvG and HV).
Th e institutional review boards had approved the study and it was conducted in accordance 
with ‘good clinical practice’ and all applicable regulatory requirements. Beforehand, all 
subjects had received study information and they had signed their written informed consent. 
All samples and data were collected prospectively.
BPH groups inclusion criteria
Men aged 50 or over, with a clinical diagnosis of BPH by medical history and physical 
examination including DRE, were considered eligible for inclusion. Other principle inclusion 
criteria for the BPH groups were an international prostate symptom score ≥ 12 points at 
screening, a prostate volume ≥ 30 ml measured by transrectal ultrasound (TRUS), a total 
serum PSA of 2.5 – 10 ng/ml at screening (extremes included), a Qmax ≥ 5 ml/s at screening, 
a post-void residual volume ≤ 250 ml (measured by suprapubic ultrasound) at screening, and 
the exclusion of PCa by a negative prostate biopsy as a result of local management within 6 
months prior to screening.
PCa groups inclusion criteria
Men aged 50 or over, with biopsy-proven, clinically localized PCa (defi ned as at least 5% of 
one biopsy core and at least 1 mm of cancer), eligible and scheduled for radical prostatectomy, 
were considered eligible for inclusion.
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BPH and PCa groups exclusion criteria
Principle exclusion criteria for both the BPH and the PCa groups were the inability to void 
spontaneously (e.g. the dependence on transurethral or suprapubic catheter for micturation), 
a history of PCa (prior to the current diagnosis for the PCa groups), previous prostatic 
surgery, a history of acute urinary retention within three months prior to screening and 
the use of any investigational or marketed 5ARI, anabolic steroids or any drug with anti-
androgenic properties within 12 months prior to screening.
Subjects
Both the subjects with BPH and the subjects with PCa were randomly assigned to take either 
0.5 mg or 3.5 mg, i.e. seven 0.5 mg capsules, dutasteride orally once daily. Th e study thus 
comprised four groups of subjects:
subjects with BPH assigned to take 0.5 mg dutasteride once daily −
subjects with BPH assigned to take 3.5 mg dutasteride once daily −
subjects with PCa assigned to take 0.5 mg dutasteride once daily −
subjects with PCa assigned to take 3.5 mg dutasteride once daily −
Th e aim was to enroll 10 subjects in each group, adding up to a total of 40. Th is number was 
chosen under the assumption of obtaining suffi  cient data to do a proper pharmacodynamic 
analysis on, while avoiding a lengthy inclusion period. As this was an exploratory/pilot study 
to establish the values for parameters needed for an appropriate power calculation, there 
were no data to base a power calculation or sample size on.
Th e relative change from baseline was assessed for all subjects separately and for all groups, 
thus all subjects served as their own controls. Th erefore, a (placebo) control group was not 
used. Th e choice for an open-label study was based on the assumption that this would not 
eff ect the changes in the PCA3 score, as this is a objective parameter.
Measurements
All subjects returned to the outpatient clinic aft er one, two and three month(s) post baseline 
and four months thereaft er for a fi nal safety follow-up visit. Th e total treatment phase 
comprised the fi rst three months. All subjects underwent TRUS to measure total prostate 
volume at baseline and at the end of the treatment phase. Blood samples for circulating levels 
of serum T, DHT and PSA were collected from all subjects at every visit except at screening 
and at the safety follow-up visit. Directly aft erwards a DRE was performed aft er which the 
subjects were asked to void. Th e fi rst voided urine was collected in a coded container with 4 
ml 0.5 M EDTA. Th e samples from the community hospital were immediately cooled to 4 °C 
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and were mailed in batches with cold packs to the laboratory in the university hospital. Th ese 
samples were processed within 48 h aft er acquisition to guarantee good sample quality. Th e 
samples taken at the university hospital were processed within one hour. Upon centrifugation 
at 4 °C and 700 g for 10 min, urinary sediments were obtained. Th ese urinary sediments 
were washed twice with ice-cold PBS (at 4 °C and 700 g for 10 min), snap-frozen in liquid 
nitrogen, and stored at -70 °C. Th e urinary sediments were spiked with 20 μg (microgram) 
of E. coli tRNA as a carrier (Roche Diagnostics, Almere, Th e Netherlands) and total RNA 
was extracted from these urinary sediments, using TRIzol Reagent (Invitrogen, Breda, Th e 
Netherlands). Eight microliters of extracted RNA was dissolved in 2.6 ml of detergent-based 
stabilization buff er, which lyses the cells and stabilizes the RNA [19]. Th e PCA3 and PSA 
mRNA transcripts were amplifi ed and quantifi ed as previously described [19]. As this was 
a pilot study, the calculated number of PCA3 or PSA mRNA transcripts was included for 
analysis even if it exceeded the assays calibrator range.
Th e PCA3 score was then calculated by dividing the number of PCA3 mRNA transcripts 
by the number of PSA mRNA transcripts detected in a given sample and multiplying the 
result by 1,000, thereby using the number of PSA mRNA transcripts to correct for the 
number of prostate cells present.
Statistical analysis
Th e results of an intention-to-treat analysis are presented.
Th e method of handling missing values was the observed-cases approach, i.e. missing 
values at post-baseline assessments were not imputed and were regarded as missing. Change 
from baseline for each man was computed as post-baseline value minus baseline value, relative 
change from baseline as change from baseline divided by baseline value.
Data were analyzed using the Statistical Package for the Social Sciences (SPSS, Chicago, 
IL, USA) version 15.0.1 for Microsoft  Windows. 
Study registry
Th is study was registered at ClinicalTrials.gov (study identifi er: NCT00375765).
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Results
Population
From April 25th 2005 to October 31st 2006, a total of 31 subjects were assessed for eligibility, 
i.e. 21 subjects with BPH and 10 subjects with PCa. Six of these subjects (fi ve with BPH 
and one with PCa) did not meet the inclusion criteria and were therefore excluded. Th us 25 
subjects (16 with BPH and nine with PCa) were enrolled and randomized to treatment. No 
subjects were lost to follow-up, discontinued treatment because of adverse eff ects or other 
reasons, or had to be excluded from analysis. Th erefore, all 25 enrolled subjects could be 
analyzed. Details are shown in Figure 1 for subjects with BPH and in Figure 2 for subjects 
with PCa.
Th e study thus comprised four groups of subjects:
eight subjects with BPH who had received 0.5 mg dutasteride once daily −
eight subjects with BPH who had received 3.5 mg dutasteride once daily −
fi ve subjects with PCa who had received 0.5 mg dutasteride once daily −
four subjects with PCa who had received 3.5 mg dutasteride once daily −
Th ree subjects with BPH were screened and two were enrolled in the community hospital, 
the rest of the subjects were screened and enrolled in the university hospital.
Baseline features
Table I shows the baseline clinical features of the two BPH groups. Table II shows the baseline 
clinical features of the two PCa groups and the prostate biopsy and radical prostatectomy 
pathology.
PCA3 score
Figure 3 shows the mean relative change from baseline PCA3 score per group aft er one, two 
and three months of dutasteride treatment.
Table III shows the PCA3 scores per subject and the mean relative change from baseline 
PCA3 score aft er one, two and three months of dutasteride treatment.
Serum DHT, T and PSA
Figure 4 shows the mean relative change from baseline serum DHT, T and PSA per group 
aft er one, two and three months of dutasteride treatment.
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Analyzed
      (n = 8)
Excluded from analysis
      (n = 0)
 
Analyzed
      (n = 8)
Excluded from analysis
      (n = 0)
Analysis 
Flow diagram of all subjects with BPH
Assessed for eligibility  (n = 21)
Excluded
      (n = 5)
– Not meeting inclusion criteria
      (n = 5)
– Refused to participate
      (n = 0)
– Other reasons 
      (n = 0)
 
Lost to follow-up
      (n=0)
Discontinued intervention
      (n = 0)
Lost to follow-up
      (n = 0)
Discontinued intervention
      (n = 0)
 
Allocation 
Follow-up 
Enrollment 
Randomization 
Allocated to 3.5 mg 
dutasteride daily:
      (n = 8)
Received allocated intervention
      (n = 8)
Did not receive allocated 
intervention
      (n = 0)
Allocated to 0.5 mg dutasteride daily:
      (n = 8)
Received allocated intervention
      (n = 8)
Did not receive allocated intervention
      (n = 0)
Figure 1. Flow diagram of all subjects with benign prostatic hyperplasia (BPH).
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Analyzed
      (n = 5)
Excluded from analysis
      (n = 0)
 
Analyzed
      (n = 4)
Excluded from analysis
      (n = 0)
Analysis 
Flow diagram of all subjects with PCa
Assessed for eligibility  (n = 10)
Excluded
      (n = 1)
– Not meeting inclusion criteria
      (n = 1)
– Refused to participate
      (n = 0)
– Other reasons 
      (n = 0)
 
Lost to follow-up
      (n=0)
Discontinued intervention
      (n = 0)
Lost to follow-up
      (n = 0)
Discontinued intervention
      (n = 0)
 
Allocation 
Follow-up 
Enrollment 
Randomization 
Allocated to 3.5 mg 
dutasteride daily:
      (n = 4)
Received allocated intervention
      (n = 4)
Did not receive allocated 
intervention
      (n = 0)
Allocated to 0.5 mg dutasteride daily:
      (n = 5)
Received allocated intervention
      (n = 5)
Did not receive allocated intervention
      (n = 0)
Figure 2. Flow diagram of all subjects with prostate cancer (PCa).
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Figure 3. Mean relative change from baseline PCA3 score per group aft er one, two and three 
months of dutasteride treatment.
Abbreviations: BPH – 0.5 mg, group of subjects with benign prostatic hyperplasia (BPH) who received 0.5 mg dutasteride; 
BPH – 3.5 mg, group of subjects with benign prostatic hyperplasia who received 3.5 mg dutasteride; PCa – 0.5 mg, group of 
subjects with prostate cancer who received 0.5 mg dutasteride; PCa - 3.5 mg, group of subjects with prostate cancer who received 
3.5 mg dutasteride.
Prostate volume
Th e mean ± SD relative change from baseline prostate volume was -11 ± 8% for the subjects 
with BPH who received 0.5 mg dutasteride, -16 ± 8% for the subjects with BPH who received 
3.5 mg dutasteride, -15 ± 11% for the subjects with PCa who received 0.5 mg dutasteride and 
-10 ± 9% for the subjects with PCa who received 3.5 mg dutasteride.
Adverse events
In general, adverse events were mild to moderate and resolved spontaneously. No serious 
adverse events were reported. Drug-related adverse events were mostly sexually related. None 
of the subjects withdrew from the study as a result of these adverse events. 
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Figure 4. Mean relative change from: A. baseline serum dihydrotestosterone (DHT), B. testosterone 
(T) and C. prostate-specifi c antigen (PSA) per group aft er one, two and three months of dutasteride 
treatment. 
Abbreviations: BPH - 0.5 mg, group of subjects with benign prostatic hyperplasia (BPH) who received 0.5 mg dutasteride; BPH 
– 3.5 mg, group of subjects with benign prostatic hyperplasia who received 3.5 mg dutasteride; PCa – 0.5 mg, group of subjects 
with prostate cancer who received 0.5 mg dutasteride; PCa – 3.5 mg, group of subjects with prostate cancer who received 3.5 mg 
dutasteride.
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Table III. PCA3 scores per subject at baseline and aft er one, two and three months of dutasteride 
treatment
Subject 
number
Group Dutasteride 
dose
PCA3 score (relative change from baseline)
Baseline Aft er 
one month
Aft er 
two months
Aft er 
three months
5 BPH 0.5 mg   1 3 (+200%) 6 (+500%) 6 (+500%)
6   6 5 (-17%) 7 (+17%) 7 (+17%)
8  12 18 (+50%) 20 (+67%) 74 ( +517%)
11  15 6 (-60%) 12 (-20%) 6 (-60%)
12  21 17 (-19%) 16 (-24%) 33 (+57%)
19  22 13 (-41%) 4 (-82%) 5 (-77%)
21  52 25 (-52%) 69 (+33%) 17 (-67%)
53  62 84 (+35%) 181 (+192%) 74 (+19%)
1 BPH 3.5 mg   9 2 (-78%) 2 (-78%) 0 (-100%)
7  19 14 (-26%) 20 (+5%) 23 (+21%)
10   5 6 (+20%) 12 (+140%) 10 (+100%)
13  18 44 (+144%) 17 (-6%) 70 (+289%)
14  24 45 (+88%) 14 (-42%) 41 (+71%)
24  44 16 (-64%) 12 (-73%) 21 (-52%)
27  24 26 (+8%) 7 (-71%) 16 (-33%)
51  35 * 19 (-46%) 31 (-11%)
9 PCa 0.5 mg 131 102 (-22%) 112 (-15%) 112 (-15%)
16  19 23 (+21%) 12 (-37%) 12 (-37%)
17  61 108 (+77%) 25 (-59%) 44 (-28%)
23  42 7 (-83%) 16 (-62%) 24 (-43%)
28 132 21 (-84%) 52 (-61%) 120 (-9%)
3 PCa 3.5 mg  15 33 (+120%) 17 (+13%) 4 (-73%)
4  85 79 (-7%) 76 (-11%) 157 (+85%)
15  19 11 (-42%) 28 (+47%) 14 (-26%)
18   6 20 (+233%) 41 (+583%) 10 (+67%)
Abbreviations: BPH, benign prostatic hyperplasia; PCa, prostate cancer; PCA3, Prostate CAncer gene 3.
* value missing
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Discussion
Th is was the fi rst study to date to investigate the eff ect of dutasteride on the PCA3 score 
longitudinally and in a dose dependent manner. In general, in all four groups both 0.5 mg 
and 3.5 mg dutasteride once daily:
had a variable eff ect on the PCA3 score −
rapidly reduced serum DHT by ≥ 90% −
over time increased serum T by 20 – 30% −
over time halved serum PSA −
decreased prostate volume by 10 – 16% −
Th e eff ect of dutasteride on the PCA3 score was not clearly time dependent, but the 
eff ect of dutasteride on serum DHT, T and PSA was.
Overall, no striking diff erences were found between the subjects with BPH who received 
0.5 mg dutasteride and those who received 3.5 mg, nor between the subjects with PCa who 
received 0.5 mg dutasteride and those who received 3.5 mg. Because of the small number of 
subjects, no statistical analysis were performed on the results.
Dutasteride had the expected eff ect on serum DHT, T and PSA, and on prostate volume. 
Th is eff ect was consistently seen across all four groups (Figure 4). In contrast, the eff ect of 
dutasteride on the PCA3 score was variable between groups (Figure 3), between subjects 
within one group and also in several subjects over time (Table III).
Several interesting observations can be made when scrutinizing the results of this study. 
Th e mean relative change from baseline PCA3 score per group shows variability over time. 
Th is is caused by the extreme values for one or two of the subjects in the group and the small 
number of subjects per group. Partin et al. have reported preliminary data indicating that the 
PCA3 score in an individual subject is quite stable over time [20]. In this study however, the 
PCA3 score did not appear to be stable in several subjects using dutasteride. In this context 
it is important to consider the absolute values for the PCA3 score in addition to the relative 
change from baseline (Table III).
In particular, subjects 8 and 53 (with BPH who received 0.5 mg dutasteride), and subjects 
13 and 14 (with BPH who received 3.5 mg dutasteride) showed large variations in PCA3 
score, including repeated values above the internationally proposed cut-off  of 35 [12-14]. 
Importantly, none of these subjects with BPH have been diagnosed with PCa during the years 
of follow-up. Th e same is true for subject 21 (with BPH who received 0.5 mg dutasteride).
In comparison, the variations in PCA3 score in the subjects with PCa were less prominent, 
especially when considering the absolute values for the PCA3 score and not just the relative 
change from baseline.
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To calculate the PCA3 score, the number of PCA3 mRNA transcripts is divided by the 
number of PSA mRNA transcripts, thereby correcting for the number of prostate cells present 
in the urine sample. Both the number of PCA3 and PSA mRNA transcripts in this fraction 
are the sum of the number of transcripts from shed PCa cells and the number of transcripts 
from shed benign prostate cells. PCA3 expression in PCa cells is 66-fold increased compared 
to PCA3 expression in benign prostate cells boosting the numerator of the fraction, while 
PSA expression in both cell types is similar, stabilizing the denominator [21]. Th is results 
in an elevated PCA3 score in subjects with PCa. Th erefore, the eff ect of dutasteride on the 
expression of PCA3 in PCa cells is pivotal in its eff ect on the PCA3 score, whereas the eff ect 
on the other three parameters in the fraction is of minor importance.
It could be expected that the mechanism of androgen regulation and thus the eff ect of 
dutasteride (and other hormonal treatment) thereon, diff ers considerably between PCa 
cells and benign prostate cells. In addition, it is very likely that this mechanism also diff ers 
between PCa cells of diff erent malignant potential, i.e. with diff erent inherent tendencies 
towards androgen independence. Th e eff ect of dutasteride on a patient’s PCA3 score can 
be an early indication of the eff ect of androgen-deprivation therapy on PCa. Th erefore, the 
infl uence of androgen-deprivation therapy on the PCA3 score should be analyzed further.
Th e most important limitation of this pilot study was the small number of subjects. 
Moreover, due to the strict inclusion and exclusion criteria its recruitment rate proved very 
slow. Aft er two and a half years the study was ended aft er randomization of 26 of the initially 
planned 40 subjects. However, it has to be noted that this study was strictly exploratory.
Conclusions
In this exploratory/pilot study the eff ect of dutasteride on the PCA3 score was variable. Th is 
should be should be taken into account while using PCA3 in diagnostics. As this study was 
exploratory, the infl uence of androgen-deprivation therapy on the PCA3 score should be 
analyzed further.
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General discussion and future perspectives
In this chapter the overview of serum and urine prostate cancer (PCa) markers from chapter 
2 is updated. Th is is followed by the general discussion and future perspectives to complete 
the thesis.
Th e phases of biomarker development
As stated in chapter 2, the fi eld of PCa marker research is vast and moreover continuously 
changing. Although there are many markers showing promise to overcome the limitations 
of prostate-specifi c antigen (PSA), when reviewing the literature on PCa marker research, 
it is sad to note that reports on many PCa markers seem limited to the promising results 
from exploratory studies. Very few PCa markers will eventually complete the path from its 
fi rst discovery in the laboratory to its commercialization and broad application in clinical 
practice, i.e. the path fr om bench to bedside.
In 2001, in an attempt to defi ne a formal structure to guide the process of biomarker 
development, the phases of screening biomarker development were described [1]. Th ese 
phases were later adapted for use in PCa (Table I) [2].
Table I. Phases of biomarker development
Phase Description
1 Preclinical exploratory studies comparing tumor tissue with non-tumor tissue to identify potential 
biomarkers
2 Development of clinical biomarker assay based on specimen that can be obtained non-invasively and assess 
diagnostic value,  ability to distinguish subjects with PCa from those without PCa
3 Asses ability of biomarker assay to detect PCa preclinically,  before it is diagnosed by prostate biopsy, 
using specimens obtained from a cohort representative of the (future) target population and stored in bio-
repositories
4 Prospective application of biomarker assay in PCa screening study,  to determine detection rate and false 
referral rate
5 Commercialization of biomarker assay and use in general population to estimate reduction in PCa mortality 
aff orded
6 Approval of biomarker assay by United States food and drug administration (FDA)
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Updated overview of PCa markers
Now follows an update of the overview of serum and urine PCa markers from chapter 2 and 
thereaft er a table indicating the present phases of development of the most promising markers 
will be provided. Again it should be noted that the PCa markers discussed below represent a 
selection based on expert opinion. No attempt was made to include all PCa markers that are 
being investigated at the moment.
1. Prostate-specifi c proteins
1.1 Prostate-specifi c antigen
A recent, high-quality review concluded that although PSA remains the corner stone of PCa 
detection, in the low PSA range new parameters are needed that improve specifi city and are 
selective for screening for aggressive lesions. In addition, PSA velocity was not shown to be 
useful in the early detection of PCa at a population level [3].
1.2 Various forms of PSA
Advances have been made in the understanding of the molecular structure of PSA. However, 
except for the use of percentage free PSA in early detection, none of the strategies based on 
the various forms of PSA have yet been suffi  ciently evaluated to warrant widespread clinical 
use [4]. Others state that percent free PSA can be useful, but only under certain defi ned 
situations [5].
1.3 Human kallikrein 2
Th e diagnostic value of human kallikrein 2 (hK2) was confi rmed in two recent retrospective 
studies [6,7]. However, a commercially available immunoassay for hK2 is at present not 
available.
1.4 Markers of neuro-endocrine diff erentiation
A role for chromogranin A (CgA) as a prognostic marker for androgen-independent disease 
remains plausible. But unfortunately, not all PCa’s have neuroendocrine diff erentiation, 
therefore CgA would only be useful in a subset of patients [8].
Th e same is true for neuron-specifi c enolase.
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2. Genetic variations in PCa
2.1 Genetic polymorphisms in cytochrome P450 enzyme superfamily
Although genetic polymorphisms in the cytochrome P450 enzyme superfamily hold 
promise to be used in the stratifi cation of men for PCa risk, a blood based assay is still under 
development.
2.2 π-class glutathione S-transferase 1 gene promoter hypermethylation
Th e diagnostic value of the detection of π-class glutathione S-transferase 1 (GSTP1) 
promoter hypermethylation by methylation-specifi c polymerase chain reaction (MSP) in 
urine samples aft er prostatic massage has been confi rmed in several reports [9-12]. In most, 
the use of a panel of hypermethylated genes is preferred over GSTP1 alone [9-11]. Th e most 
recent report was on a multicenter study in which a clinical prototype assay was used [11], 
but larger studies with a standardized protocol and commercialization of the fi nal assay will 
have to be awaited. Expressed prostatic secretions following prostatic massage plus urethral 
milking could serve as an alternative sample [13]. Furthermore, in three exploratory studies 
blood samples from men without PCa and men with PCa in diff erent stages of the disease 
were investigated, again using either GSTP1 alone [14], or a panel of hypermethylated genes 
[15,16]. Apart from being helpful in the diagnosis of PCa all three reports claim evidence of 
prognostic value.
2.3 TMPRSS2-ETS gene fusions
At present, TMPRSS2-ETS gene fusions are the focus of research of many research groups. In 
addition to the detection of the gene fusions in PCa tissue, body fl uids are examined for their 
presence. In a small exploratory study, Laxman et al. demonstrated that TMPRSS2-ERG 
gene fusions could be detected by quantitative polymerase chain reaction (PCR) in the urine 
samples of patients with PCa obtained aft er prostatic massage [17]. Hessels et al. confi rmed 
the diagnostic value of TMPRSS2-ERG gene fusions in voided urine aft er digital rectal 
examination (DRE) in a larger series and showed that using the combination of TMPRSS2-
ERG and PCA3 signifi cantly improved the sensitivity in PCa diagnosis [18]. A third study 
showed that a multiplexed model, including TMPRSS2-ERG and PCA3, outperformed 
PSA or PCA3 alone in detecting PCa [19]. Again, expressed prostatic secretions following 
prostatic massage plus urethral milking could serve as an alternative sample [13]. Th e 
TMPRSS2-ERG gene fusion could not be detected successfully in circulating tumor cells in 
blood samples from PCa patients in a small exploratory study [20].
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Early clinical research utilizing surgical cohorts have implicated a link between fusion 
status in PCa tissue and disease outcome aft er treatment, but future studies are needed before 
utilizing fusion status as a prognostic marker [21].
3. Genes overexpressed in PCa
3.1 PCA3
Apart from the studies described in this thesis, there have been several other reports on 
PCA3. An overall synopsis combining the two groups will follow at the end of this chapter.
A major step forward was the development of a standardized assay, performed on a routine 
molecular diagnostic test platform and with simple sample processing [22]. In addition, 
the DRE performed directly before collection of the urine sample was standardized, i.e. 
performing exactly three strokes per lobe by applying fi rm pressure (enough to depress the 
prostate surface approximately 1 cm) from the base to apex and from the lateral to the median 
line for each lobe [22]. Th e assay was shown to be robust and the standardized DRE proved to 
be essential, but no more than three strokes are needed [23]. In a multicenter study involving 
570 men in North America it was shown that PCA3 is independent of prostate volume 
and that its diagnostic value does not vary across diff erent PSA ranges [24]. Th e diagnostic 
accuracy of existing PCa risk calculators can be improved by the incorporation of PCA3 
[25]. Furthermore, PCA3 had clear diagnostic value in predicting biopsy outcome in 233 
North American men undergoing repeat prostate biopsy to rule out cancer [26]. A European 
multicenter study involving 463 men confi rmed this result [27]. Combining PCA3 with for 
example the TMPRSS2-ERG fusion gene and thereby analyzing urine samples with a panel 
of markers could improve the diagnostic characteristics of the urine test further [18,19]. Th e 
implications of fi nding PCA3 expression in blood samples not only from men with PCa, but 
also in men with benign prostatic hyperplasia (BPH) are not yet clear and therefore will have 
to be elucidated [28-31].
Th e prognostic value of PCA3 has also been investigated. Comparing PCA3 urine test 
results with biopsy results, Haese et al. found that the PCA3 score was signifi cantly higher in 
men with clinical stage T2 versus T1, biopsy Gleason score ≥ 7 versus < 7 PCa, and signifi cant 
versus indolent PCa (using the biopsy Epstein criteria) [27]. Others compared PCA3 urine 
test results with radical prostatectomy pathology and found that the PCA3 score correlated 
with total tumor volume [32,33]. But where Nakanishi et al. showed that the PCA3 score 
was signifi cantly higher in men with prostatectomy Gleason score ≥ 7 versus < 7 PCa, and 
Chapter 8
– 122 –
signifi cant versus indolent PCa (using the prostatectomy Epstein criteria) [32], Whitman et 
al. found men with extracapsular extension to have a higher PCA3 score than men without 
extracapsular extension [33].
Currently, a large scale validation of the diagnostic value of the PCA3 urine test in a 
screening setting is ongoing in the Rotterdam arm of the European randomized study of 
screening for prostate cancer (ERSPC) [34].
3.2 Prostate-specifi c membrane antigen
Over the last decade prostate-specifi c membrane antigen (PSMA) has been investigated as 
a PCa serum marker and as a target for radioimmunoscintigraphy or even targeted therapy. 
Nevertheless, its role as a diagnostic and therapeutic tool still is not clear [35]. 
3.3 Telomerase
Th ere seem to have been no additional reports on telomerase activity in urine as a diagnostic 
PCa marker. Two reports show evidence of telomerase activity in peripheral blood samples 
from men with PCa [36,37]. A fi nding that will have to be explored further.
3.4 Early prostate cancer antigen
A second nuclear matrix protein, early prostate cancer antigen 2 (EPCA-2), was identifi ed 
more recently. Leman et al. used the EPCA-2 assay to analyze the serum samples of again a 
case mix population of now 330 subjects in total, of whom 100 had PCa. Again sensitivity 
and specifi city for detecting PCa were over 90% [38]. Th us, the data published on EPCA 
and EPCA-2 seem very promising, but are also very preliminary, as larger validation studies 
are necessary.
3.5 Cysteine-rich secretory protein 3
Cysteine-rich secretory protein 3 (CRISP-3) does not seem to be useful as a PCa serum 
marker, as serum levels of CRISP-3 were not signifi cantly higher in PCa patients compared 
to patients with BPH [39].
3.6 Alpha-methylacyl-coenzym-A racemase
Th e quantitative detection of alpha-methylacyl-coenzym-A racemase (AMACR) transcripts 
by RT-PCR in blood samples could have diagnostic value [40]. Further exploring the 
detection of AMACR in the urine of PCa patients, the use of an anti-AMACR-immobilized 
piezoelectric-excited millimetersized sensor has been pointed out [41]. Confi rming earlier 
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data, one small study showed promising results of the quantitative detection of AMACR 
transcripts by RT-PCR in urine samples obtained aft er prostate massage [40], and these 
results were backed up by a study in a larger cohort of 232 men using a similar test method 
[42]. However, Laxman et al. did not fi nd a signifi cant predictive value for the presence 
of PCa of AMACR transcripts detected by quantitative RT-PCR in the urine of 234 men 
following DRE and before either needle biopsy or radical prostatectomy [19].
3.7 Hepsin
As stated in chapter 2, there does not seem to be a role for hepsin as a PCa serum or urine 
marker.
4. Markers of bone metabolism
4.1 Markers of bone formation
4.2 Markers of bone resorption
Over the last few years several studies involving men with PCa and bone metastases have 
confi rmed the prognostic value of several of the markers of bone formation and of bone 
resorption mentioned in chapter 2 [43-47]. However, these results will have to be confi rmed 
in prospective studies and more importantly: exactly which marker or what combination to 
use is not yet clear.
4.3 Bone morphogenetic protein 6
As part of the European P-Mark project an exploratory study using the newly developed 
assay mentioned in chapter 2 for the detection of bone morphogenetic protein 6 (BMP-6) in 
serum showed disappointing results (unpublished data). Because of this, further research on 
BMP-6 as a prognostic serum marker has been abandoned.
4.4 Osteoprotegerin
Over the last couple of years there have been very few reports on osteoprotegerin (OPG) as 
a prognostic PCa serum marker. However, data from two studies in the European P-Mark 
project suggest OPG may be a predictor of recurrence aft er curative treatment for PCa 
(unpublished data).
Table II gives a representation of the current evaluation status of the most promising 
of the abovementioned PCa markers, indicating the phase of development each marker 
presently is in.
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General discussion and future perspectives
Below, an answer will be provided to the following question: can PCA3 overcome the 
limitations of PSA? Or more precisely: can PCA3 increase the specifi city in diagnosis, 
diff erentiate between harmless and aggressive disease and identify progression towards 
androgen independence at an early stage?
In chapter 3, the diagnostic value of the PCA3 urine test was validated in a Dutch 
multicenter study. Confi rmatory results were obtained in several multicenter studies in 
other countries [24,26,27]. However, in our study we used urinary sediments as samples and 
for analysis we used the dual time resolved fl uorescence (TRF) -based reverse transcriptase-
polymerase chain reaction (RT-PCR) assay that was developed in our laboratory. In the other 
studies whole urine samples were analyzed with the transcription mediated amplifi cation 
(TMA) -based assay that was fi rst described by Groskopf et al. [22]. Th is assay has been 
commercialized by Gen-Probe Incorporated (San Diego, CA, USA). It has received a CE 
mark certifi cation which allows commercialization in Europe, but more importantly approval 
by the United States food and drug administration (FDA) is expected in 2009 (Table II).
Th e Gen-Probe PCA3 urine test combines the advantages of simple sample processing with 
the fact that it is performed on a routine molecular diagnostic test platform. As stated in 
chapters 4 and 6, a possible advantage of using the sediment of a urine sample may be that 
the size of the sample is increased by concentrating all the cells and cell fragments in the 
sediment, instead of only analyzing part of the total sample. A study comparing the results 
of both assays when performed on their standard sample type has been performed, however 
data analysis has not been completed at this time (unpublished results). Pending these results 
and considering the advantages of the now already clinically available TMA-based assay, it 
seems fair to say that this assay would be the way to go. Even so, Table II shows that PCA3 
has made it to phase 4 of marker development, but the results from the large scale validation 
of the diagnostic value of the PCA3 urine test in a screening setting in the ERSPC are 
eagerly awaited. Th ese results will also have to prove the diagnostic value of the PCA3 urine 
test in a cohort of men who are all without prior prostate biopsy. All previous multicenter 
studies on the diagnostic value of PCA3 evaluated cohorts of men either consisting solely 
of men undergoing repeat prostate biopsy [26,27], or containing a considerable percentage 
of these men [24]. In addition, by implementing the PCA3 urine test in a screening setting, 
verifi cation bias is avoided [3]. Prostatic fl uid may serve as an alternative sample type, as is 
shown in chapter 3 and has been confi rmed by others [13]. Obviously, these results await 
further confi rmation in larger cohorts. As stated, the clinical implications of the detection 
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of PCA3 expression in blood samples is at present unclear. In summary, the PCA3 urine 
test can increase the specifi city in PCa diagnosis, thereby preventing unnecessary prostate 
biopsies and thus overcoming one of the limitations of PSA.
Can the PCA3 urine test also diff erentiate between harmless and aggressive disease, 
thereby preventing overtreatment and thus overcoming another limitation of PSA? Th us far, 
the prognostic value of the PCA3 urine test has been investigated by comparing PCA3 urine 
test results with biopsy results as in chapter 5 [27], or by comparing the PCA3 score with 
radical prostatectomy pathology as in chapter 5 and 6 [32,33]. Where other groups found 
signifi cant diff erences [27,32,33], we did not. As stated in chapter 5, three variables may 
explain the diff erences. First, there are systematic diff erences in Gleason grading, which is 
best illustrated by the paradoxical high fraction of Gleason score 7 cancers in the US cohorts 
[32,33]. Second, it should be stressed that due to the original study design urinary sediments 
were analyzed in our studies, i.e. chapter 5 and 6, which may have yielded diff erent results 
than whole urine utilized in other studies. Th ird, our patient cohorts had relatively few men 
with favorable prognostic outcome. It seems the exact place of PCA3 as prognostic test 
remains subject of investigation. Importantly, both biopsy results and radical prostatectomy 
pathology are surrogate endpoints in the analysis of prognostic value, the only hard endpoint 
being death by PCa. Th erefore, the ultimate answer to the question whether PCA3 has 
prognostic value will have to come from long-term follow-up. Unfortunately, due to the 
oft en protracted course of PCa this could require a follow-up period up to 20 years. Here as 
well, it seems fair to say that the results from the phase 4 implementation of the PCA3 urine 
test in the ERSPC will shed light on the matter: for example, by providing the characteristics 
of the tumors that were detected by the PCA3 urine test and comparing these to the tumors 
that occurred clinically but that were not detected by this test. Th us, PCA3 may be able to 
diff erentiate between harmless and aggressive disease. 
In the exploratory/pilot study described in chapter 7, the eff ect of dutasteride on the 
PCA3 score was variable. Th is should be should be taken into account while using PCA3 in 
diagnostics. Th e eff ect of dutasteride on a patient’s PCA3 score may be an early indication 
of the eff ect of androgen-deprivation therapy on PCa. However, the pilot study reported 
on was strictly exploratory and the infl uence of androgen-deprivation therapy on the PCA3 
score should be analyzed further. Th erefore, at present the PCA3 urine test can not identify 
progression towards androgen independence at an early stage.
In conclusion, PCA3 can increase the specifi city in PCa diagnosis, it may be able to 
diff erentiate between harmless and aggressive disease, and at present it can not identify 
progression towards androgen independence at an early stage.
General discussion and future perspectives
– 127 –
C
ha
pt
er 8
What to do when PCA3 or any other one PCa marker can not overcome all the drawbacks 
of PSA on its own? Many have advocated the use of a panel of PCa markers. Looking at Table 
II, the logical candidates, apart form PCA3, may seem hK2, GTSP1 and OPG. However, hK2 
and OPG are analyzed in serum and the MSP urine assay for GTSP1 is not easily compatible 
with the PCA3 urine test. An alternative could be the combination of PCA3, AMACR 
and the TMPRSS2-ETS gene fusions. Th e major advantage of this combination would be 
the possibility to analyze the expression of all three marker genes at once by detecting their 
RNA in urine using just one assay. Since Gen-Probe (USA) is developing urine tests for both 
AMACR and the TMPRSS2-ETS gene fusions, results should become available within the 
next few years. Another alternative could be the implementation of PCA3 and/or other 
markers in existing PCa risk calculators.
As with most theses this one ends with the statement that the results of further research 
are awaited. However, the research in this thesis has clearly shown that molecular diagnosis 
in PCa is feasible using the PCA3 test. PCA3 has evidently proven to be of value in the 
diagnosis of PCa and it deserves a place in the urologists armamentarium.
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Prostate cancer (PCa) is the most common malignancy in Dutch men. In the year 2006, 
9,516 Dutch men were diagnosed with PCa and 2,394 died from this disease. Normally, PCa 
is diagnosed by the histological examination of prostate tissue that is obtained by ultrasound 
guided transrectal biopsy. Indications for biopsy are predominantly an increased serum level 
of prostate-specifi c antigen (PSA) and/or an aberrant digital rectal examination (DRE). PSA 
is the standard diagnostic and prognostic PCa marker. PCa awareness, leading to widespread 
use of PSA testing has led to a lower tumor stage and grade at the time of diagnosis. However, 
the use of PSA is associated with certain drawbacks. Th ere are many markers showing 
promise to overcome the limitations of PSA. Eventually, these markers should be able to 
increase the specifi city in diagnosis, diff erentiate between harmless and aggressive disease 
and identify progression towards androgen independence at an early stage. In chapter 2 an 
overview is given of serum and urine PCa markers that are currently under investigation and 
subsequently the European P-Mark project is introduced.
To improve the specifi city in PCa diagnosis and to prevent unnecessary prostate biopsies, 
especially in the serum PSA ‘gray zone’ between 3 and 15 ng/ml, the implementation of PCa-
specifi c markers is urgently needed. Th e recently discovered PCA3 is such a promising PCa 
marker. In a previous single institution study, the PCA3 urine test clearly proved to be of 
diagnostic value. Th erefore, the diagnostic performance of the PCA3 urine test was validated 
in a multicenter study which is described in chapter 3. Th e fi rst voided urine aft er digital 
rectal examination (DRE) was collected from a total of 583 men with serum PSA levels 
between 3 and 15 ng/ml who were to undergo prostate biopsies. We determined the PCA3 
score in these samples and correlated the results with the results of the prostate biopsies. 534 
men (92%) had an informative sample. Th e area under the receiver operating characteristic 
curve, a measure of the diagnostic accuracy of a test, was 0.66 for the PCA3 urine test and 
0.57 for serum PSA. Th e sensitivity for the PCA3 urine test was 65%, the specifi city was 66% 
(versus 47% for serum PSA) and the negative predictive value was 80%. In this multicenter 
study we validated the diagnostic performance of the PCA3 urine test in the largest group 
studied thus far using a PCA3 gene-based test. Th is study shows that the PCA3 urine test, 
when used as a refl ex test, can improve the specifi city in PCa diagnosis and could prevent 
many unnecessary prostate biopsies.
In the study described in chapter 4 we evaluated the PCA3 test on prostatic fl uid and 
compared this with the PCA3 test on urine in a clinical research setting. Prostatic fl uid and 
urine samples from 67 men were collected following DRE. Th e sediments were analyzed 
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using the quantitative PCA3 test. Th e results were compared with prostate biopsy results. 
Using a PCA3 score of 66 as a cut-off  value, the test on prostatic fl uid had 65% sensitivity 
for the detection of PCa, 82% specifi city and a negative predictive value of 82%. At a cut-off  
value of 43, the test on urine had 61% sensitivity, 80% specifi city and a negative predictive 
value of 80%. Th erefore, the PCA3 test can be performed on both urine and prostatic fl uid 
in the diagnosis of PCa with comparable results.
In a fi rst attempt to investigate the prognostic value of PCA3, in chapter 5 we described 
the results of a study in which the PCA3 score in urinary sediments aft er DRE was correlated 
to the biopsy Gleason score (GS) and clinical stage in 351 men who underwent prostate 
biopsies based on serum PSA levels > 3 ng/ml, an abnormal DRE, and/or a family history 
of PCa. Moreover, in 70 men who underwent a radical prostatectomy, the correlation of 
PCA3 with prostatectomy GS, tumor volume and pathological stage was assessed as well. 
In this patient cohort we could not fi nd a correlation between PCA3 and clinical stage, 
biopsy GS, radical prostatectomy GS, tumor volume, and pathological stage. Th erefore, the 
prognostic value of PCA3 as reported in other studies could not be confi rmed in our study. 
Experimental diff erences (urine sediments vs. whole urine) and cohort may explain this.
In addition to chapter 5 and to further investigate the prognostic value of PCA3, 
chapter 6 describes a study in which we analyzed the correlation between the PCA3 score 
in urinary sediments aft er DRE in 62 men and the classical prognostic parameters assessed 
in radical prostatectomy (RP) specimens, i.e. GS, tumor stage and total tumor volume. 
Moreover, we analyzed the correlation between the PCA3 score and the expression of three 
immunohistochemical markers for PCa biological aggressiveness: the cell-cell adhesion 
molecules E-cadherin and α-catenin, and the human homolog of the Drosophila enhancer 
of zeste gene (EZH2). We did not fi nd a signifi cant correlation of the PCA3 score with the 
classical prognostic parameters assessed in radical prostatectomy specimens or the expression 
of the immunohistochemical markers for PCa biological aggressiveness. However, we did 
observe a trend for a higher PCA3 score in signifi cant PCa vs. insignifi cant PCa, aberrant 
E-cadherin staining vs. normal E-cadherin staining and increased EZH2 staining vs. normal 
EZH2 staining. Th us, also in this study we could not prove the prognostic value of PCA3. 
Further research with large numbers of men and adequate follow-up is needed to provide a 
defi nitive answer to the question if PCA3 is not only a diagnostic but also a prognostic PCa 
marker.
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We present the results of the fi rst study to investigate the eff ect of dutasteride on the PCA3 
score, longitudinally and in a dose dependent manner in both men with benign prostatic 
hyperplasia (BPH) and men with PCa in chapter 7. Sixteen subjects with BPH and nine 
subjects with clinically localized PCa were enrolled in this randomized, open label, parallel-
group pilot study. Eight subjects with BPH and fi ve with PCa received 0.5 mg dutasteride 
once daily for three months, eight with BPH and four with PCa received 3.5 mg. PCA3 score, 
serum dihydrotestosterone, testosterone and PSA, and prostate volume were measured. In all 
four groups both 0.5 mg and 3.5 mg dutasteride had a variable eff ect on the PCA3 score. In 
contrast, its other eff ects were consistent as it rapidly reduced serum dihydrotestosterone by 
≥ 90%, over time increased serum testosterone by 20 – 30%, over time halved serum PSA and 
decreased prostate volume by 10 – 16%. Th erefore, in this exploratory pilot study the eff ect 
of dutasteride on the PCA3 score was variable. Th is should be should be taken into account 
while using PCA3 in diagnostics. As this study was exploratory, the infl uence of androgen-
deprivation therapy on the PCA3 score should be analyzed further.
In chapter 8 the overview of serum and urine PCa markers from chapter 2 is updated. 
In addition an answer is provided to the following question: can PCA3 overcome the 
limitations of PSA? To be more precise: can PCA3 increase the specifi city in diagnosis, 
diff erentiate between harmless and aggressive disease and identify progression towards 
androgen independence at an early stage? Th e answer is: PCA3 can increase the specifi city 
in PCa diagnosis, it may be able to diff erentiate between harmless and aggressive disease, and 
at present it can not identify progression towards androgen independence at an early stage. 
As PCA3 alone can not overcome all the drawbacks of PSA, the solution may be the use of a 
panel of new PCa markers. Logical candidates, apart from PCA3, seem human kallikrein 2, 
π-class glutathione S-transferase 1 gene promoter hypermethylation and osteoprotegerin. An 
alternative could be the combination of PCA3, alpha-methylacyl-coenzym-A racemase and 
the TMPRSS2-ETS gene fusions. Th e major advantage of the latter combination would be 
the possibility to analyze the expression of all three marker genes at once by detecting their 
RNA in urine using just one assay.
In conclusion, although the results of further research are awaited, the research in this 
thesis has clearly shown that molecular diagnosis in PCa is feasible using the PCA3 test. 
PCA3 has evidently proven to be of value in the diagnosis of PCa and therefore deserves a 
place in the urologists armamentarium.
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Moleculaire diagnostiek van prostaatkanker
PCA3
Prostaatkanker (PCa) is de meest voorkomende soort kanker bij mannen in Nederland. In 
2006 werd bij 9.516 Nederlandse mannen de diagnose PCa gesteld en overleden er 2.394 
mannen aan deze aandoening. De diagnose PCa wordt gesteld aan de hand van pathologisch 
onderzoek van prostaatbiopten die transrectaal onder echogeleide worden afgenomen. De 
indicatie voor het nemen van prostaatbiopten is normaliter een verhoogde serumwaarde van 
het prostaatspecifi ek antigeen (PSA) en/of een rectaal toucher (RT) verdacht voor PCa. 
PSA is de standaard diagnostische en prognostische marker voor PCa. De afgelopen jaren 
heeft  PCa een grotere bekendheid gekregen. Hierdoor wordt er op grote schaal gebruik 
gemaakt van de serum PSA-test. Het gevolg hiervan is dat prostaattumoren tegenwoordig 
bij presentatie minder vergevorderd zijn. Er is dus sprake van een lager tumorstadium en 
een lagere tumorgraad ten tijde van de diagnose. Echter, aan het gebruik van de serum PSA-
test kleven ook nadelen. Er zijn meerdere nieuwe veelbelovende markers die niet deze zelfde 
nadelen hebben. In de toekomst zouden deze markers de specifi citeit in de diagnostiek van 
PCa moeten kunnen verhogen, moeten kunnen diff erentiëren tussen de onschuldige en de 
agressieve vorm van PCa en de progressie naar de hormoononafh ankelijke vorm van PCa 
in een vroeg stadium moeten kunnen identifi ceren. In hoofdstuk 2 wordt een overzicht 
gegeven van de serum- en urinemarkers die momenteel worden onderzocht en daarna wordt 
het Europese P-Mark project geïntroduceerd.
Om de specifi citeit in de diagnostiek van PCa te verhogen en het onnodig uitvoeren 
van prostaatbiopsieën te voorkomen is het implementeren van meer PCa-specifi eke markers 
noodzakelijk, in het bijzonder bij serum PSA-waarden tussen 3 en 15 ng/ml. Het recent 
ontdekte PCA3 is een veelbelovende PCa-marker. In een eerdere studie, uitgevoerd in één 
ziekenhuis, bleek de PCA3-urinetest duidelijk van nut in het diagnostisch traject. Daarom 
werd de diagnostische waarde van de PCA3-urinetest gevalideerd in een multicenterstudie die 
wordt beschreven in hoofdstuk 3. Na een RT werd de eerste portie geplaste urine opgevangen 
van 583 mannen bij wie er naaldbiopten uit de prostaat genomen zouden worden op basis 
van een serum PSA-waarde tussen 3 en 15 ng/ml. In deze urinemonsters bepaalden wij de 
PCA3-score en we vergeleken die met de biopsie-uitslag. Van 534 mannen (92%) konden de 
urinemonsters succesvol worden geanalyseerd. Het oppervlak onder de ‘receiver operating 
characteristic’ (ROC) -curve, een maat voor het onderscheidende vermogen van een test, 
bedroeg 0,66 voor de PCA3-urinetest en 0,57 voor de serum PSA-test. Bij een sensitiviteit 
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van 65% voor de serum PSA-test en de PCA3-urinetest, was de specifi citeit 47% voor de 
serum PSA-test en 66% voor de PCA3-urinetest. De negatief voorspellende waarde van de 
PCA3-urinetest was 80%. In deze multicenterstudie valideerden wij de diagnostische waarde 
van de PCA3-urinetest in de grootste groep tot op heden beschreven. Uit deze studie blijkt 
dat de PCA3-urinetest, als aanvullende diagnostische test, de specifi citeit in de diagnostiek 
van PCa kan verhogen en het onnodig uitvoeren van prostaatbiopsieën kan voorkomen.
In de studie beschreven in hoofdstuk 4 onderzochten we naast urine ook prostaatvocht 
met de PCA3-test en vergeleken we de resultaten. Na een RT werd van 67 mannen een 
kleine hoeveelheid urine en prostaatvocht verzameld. Van beide monsters werd het sediment 
onderzocht met de PCA3-test. De resultaten werden vergeleken met de uitslag van daarna 
afgenomen prostaatbiopten. Wanneer een PCA3-score van 66 werd gebruikt als afk apwaarde 
voor de test op prostaatvocht, dan bedroeg de sensitiviteit voor het detecteren van PCa 65%, 
de specifi citeit 82% en de negatief voorspellende waarde 82%. Gebruikten we als afk apwaarde 
voor de test op urine een PCA3-score van 43, dan bedroeg de sensitiviteit 61%, de specifi citeit 
80% en de negatief voorspellende waarde 80%. In de diagnostiek van PCa kan de PCA3-test 
dus worden uitgevoerd op zowel urine als prostaatvocht met vergelijkbare resultaten.
In hoofdstuk 5 beschrijven we de resultaten van een eerste studie waarin de prognostische 
waarde van PCA3 werd onderzocht. Dit gebeurde door de PCA3-score in het urinesediment, 
verkregen na RT, van 351 mannen te vergelijken met de Gleason-score (GS) en het klinisch 
tumorstadium van de in de prostaatbiopten gevonden PCa. Bij deze mannen werden er 
prostaatbiopten afgenomen omdat zij een serum PSA-waarde hadden > 3 ng/ml , het RT 
verdacht was voor PCa en/of de familieanamnese positief was voor PCa. Daarnaast werd 
bij 70 mannen, die nadien een radicale prostatectomie ondergingen, de PCA3-score 
vergeleken met de GS, het tumorvolume en het pathologische tumorstadium van de in het 
prostatectomiepreparaat gevonden PCa. In dit patiëntencohort konden wij geen correlatie 
vinden tussen de PCA3-score en de GS in de prostaatbiopten, het klinisch tumorstadium, de 
GS in het prostatectomiepreparaat, het tumorvolume of het pathologische tumorstadium. 
Wij konden de prognostische waarde van PCA3, die werd gevonden in andere studies, 
dus niet bevestigen. Verschillen in analysemethode (het gebruik van urinesedimenten in 
plaats van urine) en studiepopulatie zouden hiervoor een verklaring kunnen zijn. De exacte 
prognostische waarde van PCA3 blijft  daarom onderwerp van onderzoek.
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In hoofdstuk 6, dat dient als aanvulling op hoofdstuk 5, wordt de prognostische waarde 
van PCA3 nader onderzocht. Het beschrijft  een studie waarin we de correlatie tussen de 
PCA3-score in het urinesediment na RT bij 62 mannen en de standaard prognostische 
parameters in het prostatectomiepreparaat analyseerden, te weten GS, tumorstadium en 
het totale tumorvolume. Bovendien analyseerden we de correlatie tussen de PCA3-score en 
de expressie van drie immunohistochemische markers voor de biologische agressiviteit van 
PCa: de intercellulaire adhesiemoleculen E-cadherine en α-catenine, en het eiwit EZH2. 
We vonden geen signifi cante correlatie tussen de PCA3-score en de standaard prognostische 
parameters in het prostatectomiepreparaat en/of de expressie van de immunohistochemische 
markers voor de biologische agressiviteit van PCa. Echter, we vonden wel een tendens voor 
een hogere PCA3-score bij klinisch relevante PCa versus klinisch niet relevante PCa, een 
afwijkend aankleuringspatroon voor E-cadherine versus een normaal aankleuringspatroon 
voor E-cadherine en een toegenomen aankleuring voor EZH2 versus een normale aankleuring 
voor EZH2. In deze studie konden we dus de prognostische waarde van PCA3 niet bewijzen. 
Meer onderzoek in grote groepen mannen met voldoende follow-up is vereist om een 
defi nitief antwoord te kunnen geven op de vraag of PCA3 niet alleen een diagnostische maar 
ook een prognostische PCa-marker is.
We presenteren in hoofdstuk 7 de resultaten van de eerste studie waarin het eff ect van 
dutasteride op de PCA3-score werd onderzocht, longitudinaal en gerelateerd aan de dosis, 
bij mannen met benigne prostaathyperplasie (BPH) en mannen met PCa. Zestien mannen 
met BPH en negen mannen met gelokaliseerde PCa namen deel aan dit gerandomiseerd, 
ongeblindeerd proefonderzoek. Acht mannen met BPH en vijf met PCa namen dagelijks 0,5 
mg dutasteride in gedurende drie maanden, acht mannen met BPH en vier met PCa dagelijks 
3,5 mg. De PCA3-score, de serumwaarde van dihydrotestosteron, testosteron en PSA, en 
het prostaatvolume werden gemeten. In alle vier de groepen had zowel de dosis van 0,5 mg 
als die van 3,5 mg dutasteride een variabel eff ect op de PCA3-score. Daarentegen waren de 
andere eff ecten zoals verwacht. Dutasteride verlaagde de serum dihydrotestosteronwaarde 
snel met ≥ 90%, deed na verloop van tijd de serum testosteronwaarde stijgen met 20 – 30%, 
zorgde na verloop van tijd voor een halvering van de serum PSA-waarde en reduceerde 
het prostaatvolume met 10 – 16%. In dit verkennende proefonderzoek was het eff ect van 
dutasteride op de PCA3-score dus variabel. Hiermee moet rekening worden gehouden 
wanneer men de PCA3-urinetest gebruikt in de diagnostiek van PCa. Omdat dit 
proefonderzoek zuiver verkennend was, dient de invloed van hormonale behandeling op de 
PCA3-score nader te worden onderzocht.
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In hoofdstuk 8 volgt een update van het overzicht van de serum- en urinemarkers 
uit hoofdstuk 2. Daarnaast wordt de volgende vraag beantwoord: is PCA3 de oplossing 
voor de beperkingen van PSA? Om meer precies te zijn: kan PCA3 de specifi citeit in de 
diagnostiek van PCa verhogen, diff erentiëren tussen de onschuldige en de agressieve vorm 
van PCa en de progressie naar de hormoononafh ankelijke vorm van PCa in een vroeg 
stadium identifi ceren. Het antwoord is: PCA3 kan de specifi citeit in de diagnostiek van PCa 
verhogen, kan mogelijk diff erentiëren tussen de onschuldige en de agressieve vorm van PCa 
en kan vooralsnog niet de progressie naar de hormoononafh ankelijke vorm van PCa in een 
vroeg stadium identifi ceren. Omdat PCA3 alleen niet de oplossing is voor al de beperkingen 
van PSA, ligt de oplossing wellicht bij een combinatie van enkele nieuwe PCa-markers. Naast 
PCA3, zijn logische kandidaten: humaan kallikreïne 2, π-klasse glutathione S-transferase 1 
genpromoter-hypermethylatie en/of osteoprotegerine. Een alternatief zou de combinatie van 
PCA3, α-methylacyl-coenzym-A racemase en de TMPRSS2-ETS genfusies kunnen zijn. Het 
grote voordeel van dit alternatief zou de mogelijkheid zijn om met één enkele test de expressie 
van alle drie de markergenen tegelijk te analyseren door hun RNA in urine te meten.
In conclusie, ondanks dat de resultaten van nader onderzoek moeten worden afgewacht, 
heeft  het onderzoek in dit proefschrift  duidelijk aangetoond dat moleculaire diagnostiek van 
PCa mogelijk is met de PCA3-test. De aanvullende waarde van PCA3 in de diagnostiek van 
PCa is evident en daarom verdient de PCA3-test een plaats in het diagnostisch arsenaal van 
de uroloog.
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